JP6111268B2 - Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 - Google Patents

Info

Publication number

JP6111268B2

JP6111268B2 JP2014552736A JP2014552736A JP6111268B2 JP 6111268 B2 JP6111268 B2 JP 6111268B2 JP 2014552736 A JP2014552736 A JP 2014552736A JP 2014552736 A JP2014552736 A JP 2014552736A JP 6111268 B2 JP6111268 B2 JP 6111268B2

Authority

JP

Japan

Prior art keywords

pyridine

dihydro

carboxylic acid

furo

amide

Prior art date

2012-01-20

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired - Fee Related

Links

• Espacenet
• Global Dossier
• Discuss

• -1 Heterocyclic amide Chemical class 0.000 title claims description 120
• 102100037602 P2X purinoceptor 7 Human genes 0.000 title description 19
• 101710189965 P2X purinoceptor 7 Proteins 0.000 title description 12
• 239000002464 receptor antagonist Substances 0.000 title description 5
• 229940044551 receptor antagonist Drugs 0.000 title description 5
• 150000001875 compounds Chemical class 0.000 claims description 226
• 150000003839 salts Chemical class 0.000 claims description 96
• 125000001424 substituent group Chemical group 0.000 claims description 90
• 125000003118 aryl group Chemical group 0.000 claims description 87
• 229910052736 halogen Inorganic materials 0.000 claims description 65
• 239000000203 mixture Substances 0.000 claims description 64
• 125000000217 alkyl group Chemical group 0.000 claims description 59
• 150000002367 halogens Chemical class 0.000 claims description 58
• 125000001072 heteroaryl group Chemical group 0.000 claims description 56
• 208000002193 Pain Diseases 0.000 claims description 52
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
• 125000003545 alkoxy group Chemical group 0.000 claims description 31
• 229910052739 hydrogen Inorganic materials 0.000 claims description 31
• 239000001257 hydrogen Substances 0.000 claims description 31
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 30
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
• 125000000623 heterocyclic group Chemical group 0.000 claims description 28
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 25
• 125000003709 fluoroalkyl group Chemical group 0.000 claims description 25
• 208000035475 disorder Diseases 0.000 claims description 21
• 230000002265 prevention Effects 0.000 claims description 21
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 20
• 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 20
• 201000010099 disease Diseases 0.000 claims description 20
• 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims description 19
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 18
• 206010028980 Neoplasm Diseases 0.000 claims description 15
• 125000005002 aryl methyl group Chemical group 0.000 claims description 15
• 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 14
• 201000011510 cancer Diseases 0.000 claims description 14
• 239000003814 drug Substances 0.000 claims description 14
• 230000002757 inflammatory effect Effects 0.000 claims description 14
• 125000006536 (C1-C2)alkoxy group Chemical group 0.000 claims description 13
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 13
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 13
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
• 229910052731 fluorine Inorganic materials 0.000 claims description 12
• 239000011737 fluorine Substances 0.000 claims description 12
• 150000001408 amides Chemical class 0.000 claims description 10
• 208000010668 atopic eczema Diseases 0.000 claims description 9
• 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 8
• 208000017520 skin disease Diseases 0.000 claims description 8
• BDWHVFDZURHALZ-LURJTMIESA-N (3r)-2,3-dihydrofuro[2,3-b]pyridine-3-carboxylic acid Chemical compound C1=CC=C2[C@@H](C(=O)O)COC2=N1 BDWHVFDZURHALZ-LURJTMIESA-N 0.000 claims description 7
• 208000018522 Gastrointestinal disease Diseases 0.000 claims description 7
• 230000001363 autoimmune Effects 0.000 claims description 7
• 238000004519 manufacturing process Methods 0.000 claims description 7
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
• 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 6
• 208000025609 Urogenital disease Diseases 0.000 claims description 6
• 230000000172 allergic effect Effects 0.000 claims description 6
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
• 230000003187 abdominal effect Effects 0.000 claims description 5
• 208000030533 eye disease Diseases 0.000 claims description 5
• 230000000626 neurodegenerative effect Effects 0.000 claims description 5
• 230000000414 obstructive effect Effects 0.000 claims description 5
• BDWHVFDZURHALZ-ZCFIWIBFSA-N (3s)-2,3-dihydrofuro[2,3-b]pyridine-3-carboxylic acid Chemical compound C1=CC=C2[C@H](C(=O)O)COC2=N1 BDWHVFDZURHALZ-ZCFIWIBFSA-N 0.000 claims description 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
• 208000023504 respiratory system disease Diseases 0.000 claims description 4
• 208000012659 Joint disease Diseases 0.000 claims description 3
• 239000004480 active ingredient Substances 0.000 claims description 3
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
• CZPLKOIQGWGITH-UHFFFAOYSA-N n-[(2,4,6-trichlorophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1C2=CC=CN=C2OC1 CZPLKOIQGWGITH-UHFFFAOYSA-N 0.000 claims description 3
• TXEBNCWNZYHMND-UHFFFAOYSA-N n-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CNC(=O)C2C3=CC=CN=C3OCC2)=C1Cl TXEBNCWNZYHMND-UHFFFAOYSA-N 0.000 claims description 3
• YQAIIZWOJNOYFT-JKSUJKDBSA-N (3r)-n-[(1r)-1,2,3,4-tetrahydronaphthalen-1-yl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2[C@H]1C(=O)N[C@H]1C2=CC=CC=C2CCC1 YQAIIZWOJNOYFT-JKSUJKDBSA-N 0.000 claims description 2
• GOCMKLPZAAFVSY-RNCFNFMXSA-N (3r)-n-[(1r)-1-(2,4-dichlorophenyl)ethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1([C@H](NC(=O)[C@@H]2C3=CC=CN=C3OC2)C)=CC=C(Cl)C=C1Cl GOCMKLPZAAFVSY-RNCFNFMXSA-N 0.000 claims description 2
• UCBFJVRADZPIPD-GXTWGEPZSA-N (3r)-n-[(1s)-1-(2,4-dichlorophenyl)-2-hydroxyethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1([C@H](NC(=O)[C@@H]2C3=CC=CN=C3OC2)CO)=CC=C(Cl)C=C1Cl UCBFJVRADZPIPD-GXTWGEPZSA-N 0.000 claims description 2
• NWENONKHUNGCRP-UONOGXRCSA-N (3r)-n-[(1s)-1-cyclohexyl-2-hydroxyethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1([C@H](NC(=O)[C@@H]2C3=CC=CN=C3OC2)CO)CCCCC1 NWENONKHUNGCRP-UONOGXRCSA-N 0.000 claims description 2
• JKXVXPCVBYFYGE-ZDUSSCGKSA-N (3r)-n-[(2,4-dichloro-6-methylphenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound CC1=CC(Cl)=CC(Cl)=C1CNC(=O)[C@@H]1C2=CC=CN=C2OC1 JKXVXPCVBYFYGE-ZDUSSCGKSA-N 0.000 claims description 2
• CPNMRHDPBLHWCX-NSHDSACASA-N (3r)-n-[(2-bromo-4,6-dichlorophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound BrC1=CC(Cl)=CC(Cl)=C1CNC(=O)[C@@H]1C2=CC=CN=C2OC1 CPNMRHDPBLHWCX-NSHDSACASA-N 0.000 claims description 2
• GYTSAQDZDZROII-ZDUSSCGKSA-N (3r)-n-[[2,4-dichloro-6-(hydroxymethyl)phenyl]methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound OCC1=CC(Cl)=CC(Cl)=C1CNC(=O)[C@@H]1C2=CC=CN=C2OC1 GYTSAQDZDZROII-ZDUSSCGKSA-N 0.000 claims description 2
• YQAIIZWOJNOYFT-HZPDHXFCSA-N (3s)-n-[(1r)-1,2,3,4-tetrahydronaphthalen-1-yl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2[C@@H]1C(=O)N[C@H]1C2=CC=CC=C2CCC1 YQAIIZWOJNOYFT-HZPDHXFCSA-N 0.000 claims description 2
• UCBFJVRADZPIPD-TZMCWYRMSA-N (3s)-n-[(1s)-1-(2,4-dichlorophenyl)-2-hydroxyethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1([C@H](NC(=O)[C@H]2C3=CC=CN=C3OC2)CO)=CC=C(Cl)C=C1Cl UCBFJVRADZPIPD-TZMCWYRMSA-N 0.000 claims description 2
• NWENONKHUNGCRP-ZIAGYGMSSA-N (3s)-n-[(1s)-1-cyclohexyl-2-hydroxyethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1([C@H](NC(=O)[C@H]2C3=CC=CN=C3OC2)CO)CCCCC1 NWENONKHUNGCRP-ZIAGYGMSSA-N 0.000 claims description 2
• JKXVXPCVBYFYGE-CYBMUJFWSA-N (3s)-n-[(2,4-dichloro-6-methylphenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound CC1=CC(Cl)=CC(Cl)=C1CNC(=O)[C@H]1C2=CC=CN=C2OC1 JKXVXPCVBYFYGE-CYBMUJFWSA-N 0.000 claims description 2
• CPNMRHDPBLHWCX-LLVKDONJSA-N (3s)-n-[(2-bromo-4,6-dichlorophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound BrC1=CC(Cl)=CC(Cl)=C1CNC(=O)[C@H]1C2=CC=CN=C2OC1 CPNMRHDPBLHWCX-LLVKDONJSA-N 0.000 claims description 2
• ZNKLJUGMIKZITC-HUUCEWRRSA-N (3s)-n-[(2s)-2-morpholin-4-yl-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1=NC(C(F)(F)F)=NC=C1[C@H](N1CCOCC1)CNC(=O)[C@H]1C2=CC=CN=C2OC1 ZNKLJUGMIKZITC-HUUCEWRRSA-N 0.000 claims description 2
• GYTSAQDZDZROII-CYBMUJFWSA-N (3s)-n-[[2,4-dichloro-6-(hydroxymethyl)phenyl]methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound OCC1=CC(Cl)=CC(Cl)=C1CNC(=O)[C@H]1C2=CC=CN=C2OC1 GYTSAQDZDZROII-CYBMUJFWSA-N 0.000 claims description 2
• VXKSAGLRTGWRKM-GFCCVEGCSA-N (4r)-n-[(2,4-dichloro-6-methylphenyl)methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound CC1=CC(Cl)=CC(Cl)=C1CNC(=O)[C@H]1C2=CC=CN=C2OCC1 VXKSAGLRTGWRKM-GFCCVEGCSA-N 0.000 claims description 2
• VXKSAGLRTGWRKM-LBPRGKRZSA-N (4s)-n-[(2,4-dichloro-6-methylphenyl)methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound CC1=CC(Cl)=CC(Cl)=C1CNC(=O)[C@@H]1C2=CC=CN=C2OCC1 VXKSAGLRTGWRKM-LBPRGKRZSA-N 0.000 claims description 2
• 208000020084 Bone disease Diseases 0.000 claims description 2
• NTLMQVKUQKGLEP-UHFFFAOYSA-N ClC1=C(CNC(=O)C2(COC3=NC=CC=C32)F)C=CC=C1C(F)(F)F Chemical compound ClC1=C(CNC(=O)C2(COC3=NC=CC=C32)F)C=CC=C1C(F)(F)F NTLMQVKUQKGLEP-UHFFFAOYSA-N 0.000 claims description 2
• GRDUOGMEQHALMG-UHFFFAOYSA-N ClC1=C(CNC(=O)C2COC3=NC=CC=C32)C(=CC=C1)CO Chemical compound ClC1=C(CNC(=O)C2COC3=NC=CC=C32)C(=CC=C1)CO GRDUOGMEQHALMG-UHFFFAOYSA-N 0.000 claims description 2
• HYNOMRVXCUSONF-UHFFFAOYSA-N ClC1=C(CNC(=O)C2COC3=NC=CC=C32)C=CC=C1C#N Chemical compound ClC1=C(CNC(=O)C2COC3=NC=CC=C32)C=CC=C1C#N HYNOMRVXCUSONF-UHFFFAOYSA-N 0.000 claims description 2
• YEKAADQJGPRWQG-UHFFFAOYSA-N ClC1=CC(=C(CNC(=O)C2COC3=NC=CC=C32)C=C1)CO Chemical compound ClC1=CC(=C(CNC(=O)C2COC3=NC=CC=C32)C=C1)CO YEKAADQJGPRWQG-UHFFFAOYSA-N 0.000 claims description 2
• XCXPKEUZIQGOOP-UHFFFAOYSA-N FC=1C=C(CNC(=O)C2COC3=NC=CC=C32)C=CC1OC(F)(F)F Chemical compound FC=1C=C(CNC(=O)C2COC3=NC=CC=C32)C=CC1OC(F)(F)F XCXPKEUZIQGOOP-UHFFFAOYSA-N 0.000 claims description 2
• QAWCAQCOBWYFOU-UHFFFAOYSA-N N-(4,6-dichloro-3-oxo-1,2-dihydroinden-2-yl)-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC=1C=C2CC(C(C2=C(C1)Cl)=O)NC(=O)C1COC2=NC=CC=C21 QAWCAQCOBWYFOU-UHFFFAOYSA-N 0.000 claims description 2
• NZCFDDMETPJUAL-UHFFFAOYSA-N N-(7-bromo-2,3-dihydro-1H-inden-1-yl)-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound Brc1cccc2CCC(NC(=O)C3COc4ncccc34)c12 NZCFDDMETPJUAL-UHFFFAOYSA-N 0.000 claims description 2
• LGKRSTOHNCFTGP-UHFFFAOYSA-N N-[(1-phenylcyclohexyl)methyl]-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1(=CC=CC=C1)C1(CCCCC1)CNC(=O)C1CCOC2=NC=CC=C21 LGKRSTOHNCFTGP-UHFFFAOYSA-N 0.000 claims description 2
• YHXBKTLNTIEPPE-UHFFFAOYSA-N n-(1-carbamoylcyclopentyl)-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2C1C(=O)NC1(C(=O)N)CCCC1 YHXBKTLNTIEPPE-UHFFFAOYSA-N 0.000 claims description 2
• NHBSEELJPOLMEY-UHFFFAOYSA-N n-(1-cycloheptyl-2-hydroxyethyl)-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1COC2=NC=CC=C2C1C(=O)NC(CO)C1CCCCCC1 NHBSEELJPOLMEY-UHFFFAOYSA-N 0.000 claims description 2
• DLRZZEOVLZQKDQ-UHFFFAOYSA-N n-(2-carbamoylcyclohexyl)-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound NC(=O)C1CCCCC1NC(=O)C1C2=CC=CN=C2OC1 DLRZZEOVLZQKDQ-UHFFFAOYSA-N 0.000 claims description 2
• BSSIZAMQALBCFN-UHFFFAOYSA-N n-(2-phenylcyclopropyl)-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2C1C(=O)NC1CC1C1=CC=CC=C1 BSSIZAMQALBCFN-UHFFFAOYSA-N 0.000 claims description 2
• KWFRKVWOJFLNAF-UHFFFAOYSA-N n-(5,7-dichloro-2,3-dihydro-1h-inden-1-yl)-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2C1C(=O)NC1CCC2=C1C(Cl)=CC(Cl)=C2 KWFRKVWOJFLNAF-UHFFFAOYSA-N 0.000 claims description 2
• QQRACPZDYASJLD-UHFFFAOYSA-N n-(7-chloro-2,3-dihydro-1h-inden-1-yl)-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2C1C(=O)NC1CCC2=C1C(Cl)=CC=C2 QQRACPZDYASJLD-UHFFFAOYSA-N 0.000 claims description 2
• QMNHSDVRJFYAOM-UHFFFAOYSA-N n-[(1-hydroxycyclohexyl)methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1COC2=NC=CC=C2C1C(=O)NCC1(O)CCCCC1 QMNHSDVRJFYAOM-UHFFFAOYSA-N 0.000 claims description 2
• GACLCUGVJCORSZ-JOPIAHFSSA-N n-[(1s)-1-(2,4-dichlorophenyl)-2-hydroxyethyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1([C@H](NC(=O)C2C3=CC=CN=C3OCC2)CO)=CC=C(Cl)C=C1Cl GACLCUGVJCORSZ-JOPIAHFSSA-N 0.000 claims description 2
• DISGODOQECPEBV-AWKYBWMHSA-N n-[(1s)-1-cyclohexyl-2-hydroxyethyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1([C@H](NC(=O)C2C3=CC=CN=C3OCC2)CO)CCCCC1 DISGODOQECPEBV-AWKYBWMHSA-N 0.000 claims description 2
• KXJALDIFOMZQBY-DMJDIKPUSA-N n-[(1s,2r)-2-hydroxy-2,3-dihydro-1h-inden-1-yl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2C1C(=O)N[C@H]1C2=CC=CC=C2C[C@H]1O KXJALDIFOMZQBY-DMJDIKPUSA-N 0.000 claims description 2
• POTPTCKDGKONSJ-UHFFFAOYSA-N n-[(2,3-dichlorophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC1=CC=CC(CNC(=O)C2C3=CC=CN=C3OC2)=C1Cl POTPTCKDGKONSJ-UHFFFAOYSA-N 0.000 claims description 2
• KEUHEJZXACRALD-UHFFFAOYSA-N n-[(2,3-dichlorophenyl)methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound ClC1=CC=CC(CNC(=O)C2C3=CC=CN=C3OCC2)=C1Cl KEUHEJZXACRALD-UHFFFAOYSA-N 0.000 claims description 2
• AEGZTOJJSYYBJD-UHFFFAOYSA-N n-[(2,3-dichlorophenyl)methyl]-3-fluoro-2h-furo[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2C1(F)C(=O)NCC1=CC=CC(Cl)=C1Cl AEGZTOJJSYYBJD-UHFFFAOYSA-N 0.000 claims description 2
• WWPUQDAHZIEYBE-UHFFFAOYSA-N n-[(2,4-dichloro-6-cyclopropylphenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C=1C(Cl)=CC(Cl)=C(CNC(=O)C2C3=CC=CN=C3OC2)C=1C1CC1 WWPUQDAHZIEYBE-UHFFFAOYSA-N 0.000 claims description 2
• AOUAOQLBLIAOBQ-UHFFFAOYSA-N n-[(2,4-dichloro-6-ethenylphenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C=CC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1C2=CC=CN=C2OC1 AOUAOQLBLIAOBQ-UHFFFAOYSA-N 0.000 claims description 2
• FUJRBBBWJFMIPA-UHFFFAOYSA-N n-[(2,4-dichloro-6-ethylphenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound CCC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1C2=CC=CN=C2OC1 FUJRBBBWJFMIPA-UHFFFAOYSA-N 0.000 claims description 2
• CGMWYADLOSRXKZ-UHFFFAOYSA-N n-[(2,4-dichloro-6-fluorophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound FC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1C2=CC=CN=C2OC1 CGMWYADLOSRXKZ-UHFFFAOYSA-N 0.000 claims description 2
• QNYCUCZHDGLXEE-UHFFFAOYSA-N n-[(2,4-dichloro-6-methoxyphenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound COC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1C2=CC=CN=C2OC1 QNYCUCZHDGLXEE-UHFFFAOYSA-N 0.000 claims description 2
• UPYNKNFIYBQHDQ-UHFFFAOYSA-N n-[(2,4-dichloro-6-methylphenyl)methyl]-3-fluoro-2h-furo[2,3-b]pyridine-3-carboxamide Chemical compound CC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1(F)C2=CC=CN=C2OC1 UPYNKNFIYBQHDQ-UHFFFAOYSA-N 0.000 claims description 2
• HXBZTCDIUICWPT-UHFFFAOYSA-N n-[(2,4-dichloro-6-methylphenyl)methyl]-4-fluoro-2,3-dihydropyrano[2,3-b]pyridine-4-carboxamide Chemical compound CC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1(F)C2=CC=CN=C2OCC1 HXBZTCDIUICWPT-UHFFFAOYSA-N 0.000 claims description 2
• BTALXIJJHIEENJ-UHFFFAOYSA-N n-[(2,4-dichlorophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CNC(=O)C1C2=CC=CN=C2OC1 BTALXIJJHIEENJ-UHFFFAOYSA-N 0.000 claims description 2
• HBKPYZFWFANAAR-UHFFFAOYSA-N n-[(2,4-dichlorophenyl)methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CNC(=O)C1C2=CC=CN=C2OCC1 HBKPYZFWFANAAR-UHFFFAOYSA-N 0.000 claims description 2
• APBSBRTWUOTGSH-UHFFFAOYSA-N n-[(2-chloro-4-cyanophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC1=CC(C#N)=CC=C1CNC(=O)C1C2=CC=CN=C2OC1 APBSBRTWUOTGSH-UHFFFAOYSA-N 0.000 claims description 2
• HXOIZKMQBOLMEP-UHFFFAOYSA-N n-[(2-chloro-4-fluorophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC1=CC(F)=CC=C1CNC(=O)C1C2=CC=CN=C2OC1 HXOIZKMQBOLMEP-UHFFFAOYSA-N 0.000 claims description 2
• RJRVAQBBIXMFOZ-UHFFFAOYSA-N n-[(2-chloro-4-fluorophenyl)methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound ClC1=CC(F)=CC=C1CNC(=O)C1C2=CC=CN=C2OCC1 RJRVAQBBIXMFOZ-UHFFFAOYSA-N 0.000 claims description 2
• FSQUDQHXGSGBJC-UHFFFAOYSA-N n-[(3-chloro-2-methylphenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound CC1=C(Cl)C=CC=C1CNC(=O)C1C2=CC=CN=C2OC1 FSQUDQHXGSGBJC-UHFFFAOYSA-N 0.000 claims description 2
• VMKAYXRJJXYVST-UHFFFAOYSA-N n-[(3-chloro-2-methylphenyl)methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound CC1=C(Cl)C=CC=C1CNC(=O)C1C2=CC=CN=C2OCC1 VMKAYXRJJXYVST-UHFFFAOYSA-N 0.000 claims description 2
• FMOPHLXDWYWPJV-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1CNC(=O)C1C2=CC=CN=C2OC1 FMOPHLXDWYWPJV-UHFFFAOYSA-N 0.000 claims description 2
• ZFJPYPHBQJXGNJ-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1CNC(=O)C1C2=CC=CN=C2OCC1 ZFJPYPHBQJXGNJ-UHFFFAOYSA-N 0.000 claims description 2
• RRAVUWRNJPHVGL-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-n-methyl-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2C1C(=O)N(C)CC1=CC=C(Cl)C=C1 RRAVUWRNJPHVGL-UHFFFAOYSA-N 0.000 claims description 2
• KAJBEUUBNBSJGV-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-n-methyl-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1COC2=NC=CC=C2C1C(=O)N(C)CC1=CC=C(Cl)C=C1 KAJBEUUBNBSJGV-UHFFFAOYSA-N 0.000 claims description 2
• ZWWSHVDBQKBJJT-UHFFFAOYSA-N n-[(4-phenoxyphenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2C1C(=O)NCC(C=C1)=CC=C1OC1=CC=CC=C1 ZWWSHVDBQKBJJT-UHFFFAOYSA-N 0.000 claims description 2
• ZTYMSNJZLMPYMB-UHFFFAOYSA-N n-[(4-phenoxyphenyl)methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1COC2=NC=CC=C2C1C(=O)NCC(C=C1)=CC=C1OC1=CC=CC=C1 ZTYMSNJZLMPYMB-UHFFFAOYSA-N 0.000 claims description 2
• CQACQEJBTZQGGL-UHFFFAOYSA-N n-[1-(2,4-dichlorophenyl)cyclopropyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1C1(NC(=O)C2C3=CC=CN=C3OCC2)CC1 CQACQEJBTZQGGL-UHFFFAOYSA-N 0.000 claims description 2
• ROGUKCZRCNCHKF-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C1C2=CC=CN=C2OC1 ROGUKCZRCNCHKF-UHFFFAOYSA-N 0.000 claims description 2
• UAJVLAUYNLOPNG-UHFFFAOYSA-N n-[2-(2,4-dichlorophenyl)ethyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CCNC(=O)C1C2=CC=CN=C2OCC1 UAJVLAUYNLOPNG-UHFFFAOYSA-N 0.000 claims description 2
• UUSNDWTVEVANBB-UHFFFAOYSA-N n-[2-(2-cyclopropylpyrimidin-5-yl)-2-morpholin-4-ylethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1OC2=NC=CC=C2C1C(=O)NCC(C=1C=NC(=NC=1)C1CC1)N1CCOCC1 UUSNDWTVEVANBB-UHFFFAOYSA-N 0.000 claims description 2
• WKQXOBVXZVHDBY-UHFFFAOYSA-N n-[2-(4,4-difluoropiperidin-1-yl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1=NC(C(F)(F)F)=NC=C1C(N1CCC(F)(F)CC1)CNC(=O)C1C2=CC=CN=C2OC1 WKQXOBVXZVHDBY-UHFFFAOYSA-N 0.000 claims description 2
• LHYBTGRAPULROV-UHFFFAOYSA-N n-[2-(4,4-difluoropiperidin-1-yl)-2-[4-(trifluoromethyl)phenyl]ethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C(N1CCC(F)(F)CC1)CNC(=O)C1C2=CC=CN=C2OC1 LHYBTGRAPULROV-UHFFFAOYSA-N 0.000 claims description 2
• FXEONGMZWAKNRV-UHFFFAOYSA-N n-[2-(6-methoxypyridin-3-yl)-2-morpholin-4-ylethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1=NC(OC)=CC=C1C(N1CCOCC1)CNC(=O)C1C2=CC=CN=C2OC1 FXEONGMZWAKNRV-UHFFFAOYSA-N 0.000 claims description 2
• AMGKYSLBMSZFJT-UHFFFAOYSA-N n-[2-(6-methylpyridin-3-yl)-2-morpholin-4-ylethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1=NC(C)=CC=C1C(N1CCOCC1)CNC(=O)C1C2=CC=CN=C2OC1 AMGKYSLBMSZFJT-UHFFFAOYSA-N 0.000 claims description 2
• XXWWSCLZNBOIMM-UHFFFAOYSA-N n-[2-morpholin-4-yl-2-[6-(trifluoromethyl)pyridin-3-yl]ethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1=NC(C(F)(F)F)=CC=C1C(N1CCOCC1)CNC(=O)C1C2=CC=CN=C2OC1 XXWWSCLZNBOIMM-UHFFFAOYSA-N 0.000 claims description 2
• ICVYFJUGDDMKTI-UHFFFAOYSA-N n-[3-(2,4-dichlorophenyl)propyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1CCCNC(=O)C1C2=CC=CN=C2OC1 ICVYFJUGDDMKTI-UHFFFAOYSA-N 0.000 claims description 2
• YGINLXCUJZESTO-UHFFFAOYSA-N n-[[1-(6-chloropyridin-3-yl)-4,4-difluorocyclohexyl]methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1CC(F)(F)CCC1(C=1C=NC(Cl)=CC=1)CNC(=O)C1C2=CC=CN=C2OCC1 YGINLXCUJZESTO-UHFFFAOYSA-N 0.000 claims description 2
• OCGNNUGNGDLYIX-UHFFFAOYSA-N n-[[1-(6-chloropyridin-3-yl)cyclohexyl]methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1=NC(Cl)=CC=C1C1(CNC(=O)C2C3=CC=CN=C3OCC2)CCCCC1 OCGNNUGNGDLYIX-UHFFFAOYSA-N 0.000 claims description 2
• IXCGZYKMXAHFMM-UHFFFAOYSA-N n-[[2,4-dichloro-6-(2-hydroxyethoxy)phenyl]methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound OCCOC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1C2=CC=CN=C2OC1 IXCGZYKMXAHFMM-UHFFFAOYSA-N 0.000 claims description 2
• XOMZGLXVHMQEEG-UHFFFAOYSA-N n-[[2,4-dichloro-6-(2-hydroxyethoxymethyl)phenyl]methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound OCCOCC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1C2=CC=CN=C2OC1 XOMZGLXVHMQEEG-UHFFFAOYSA-N 0.000 claims description 2
• ZQJVKJOQFKOGOL-UHFFFAOYSA-N n-[[2,4-dichloro-6-(hydroxymethyl)phenyl]methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound OCC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1C2=CC=CN=C2OCC1 ZQJVKJOQFKOGOL-UHFFFAOYSA-N 0.000 claims description 2
• NETGQGUFXRUGFA-UHFFFAOYSA-N n-[[2,4-dichloro-6-(methoxymethyl)phenyl]methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound COCC1=CC(Cl)=CC(Cl)=C1CNC(=O)C1C2=CC=CN=C2OC1 NETGQGUFXRUGFA-UHFFFAOYSA-N 0.000 claims description 2
• BMXFYLRLYGVKMS-UHFFFAOYSA-N n-[[2,4-dichloro-6-(trifluoromethyl)phenyl]methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC(Cl)=CC(Cl)=C1CNC(=O)C1C2=CC=CN=C2OC1 BMXFYLRLYGVKMS-UHFFFAOYSA-N 0.000 claims description 2
• MJUQXVFIESWKTR-UHFFFAOYSA-N n-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=CC=CC(CNC(=O)C2C3=CC=CN=C3OC2)=C1Cl MJUQXVFIESWKTR-UHFFFAOYSA-N 0.000 claims description 2
• HACJQFJVTUVVQQ-UHFFFAOYSA-N n-[[2-chloro-4-(trifluoromethyl)phenyl]methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC1=CC(C(F)(F)F)=CC=C1CNC(=O)C1C2=CC=CN=C2OC1 HACJQFJVTUVVQQ-UHFFFAOYSA-N 0.000 claims description 2
• CYUWZDWKCCCIIT-UHFFFAOYSA-N n-[[3-chloro-2-(trifluoromethyl)phenyl]methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound FC(F)(F)C1=C(Cl)C=CC=C1CNC(=O)C1C2=CC=CN=C2OC1 CYUWZDWKCCCIIT-UHFFFAOYSA-N 0.000 claims description 2
• OHZAAOPIQYFLOW-UHFFFAOYSA-N n-[[3-fluoro-4-(trifluoromethoxy)phenyl]methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1=C(OC(F)(F)F)C(F)=CC(CNC(=O)C2C3=CC=CN=C3OCC2)=C1 OHZAAOPIQYFLOW-UHFFFAOYSA-N 0.000 claims description 2
• AUTYGILTJMPOGA-UHFFFAOYSA-N n-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)C1C2=CC=CN=C2OC1 AUTYGILTJMPOGA-UHFFFAOYSA-N 0.000 claims description 2
• JLZWLOFKXAWPEU-UHFFFAOYSA-N n-[[4-(trifluoromethyl)phenyl]methyl]-3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(=O)C1C2=CC=CN=C2OCC1 JLZWLOFKXAWPEU-UHFFFAOYSA-N 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 13
• VBZWZWLSSSMRTJ-YSSOQSIOSA-N N-[(1R)-2,3-dihydro-1H-inden-1-yl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound [C@H]1(CCC2=CC=CC=C12)NC(=O)C1COC2=NC=CC=C21 VBZWZWLSSSMRTJ-YSSOQSIOSA-N 0.000 claims 1
• 210000000988 bone and bone Anatomy 0.000 claims 1
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 148
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 104
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 102
• 230000015572 biosynthetic process Effects 0.000 description 92
• 238000003786 synthesis reaction Methods 0.000 description 91
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 78
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 74
• 235000019439 ethyl acetate Nutrition 0.000 description 74
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 63
• 239000000243 solution Substances 0.000 description 62
• 239000012044 organic layer Substances 0.000 description 46
• 239000011541 reaction mixture Substances 0.000 description 44
• 239000002904 solvent Substances 0.000 description 44
• 239000007787 solid Substances 0.000 description 41
• YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 40
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
• 238000000034 method Methods 0.000 description 34
• 125000004356 hydroxy functional group Chemical group O* 0.000 description 32
• 238000001514 detection method Methods 0.000 description 31
• 239000000047 product Substances 0.000 description 31
• 125000004432 carbon atom Chemical group C* 0.000 description 26
• 238000004296 chiral HPLC Methods 0.000 description 26
• 239000012267 brine Substances 0.000 description 25
• 238000000746 purification Methods 0.000 description 25
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 25
• 238000004440 column chromatography Methods 0.000 description 24
• 125000001153 fluoro group Chemical group F* 0.000 description 22
• 229920006395 saturated elastomer Polymers 0.000 description 20
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 19
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
• 230000001684 chronic effect Effects 0.000 description 18
• 210000004027 cell Anatomy 0.000 description 17
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 16
• 229910052757 nitrogen Inorganic materials 0.000 description 16
• 238000006243 chemical reaction Methods 0.000 description 15
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 15
• 150000002825 nitriles Chemical class 0.000 description 15
• 150000001412 amines Chemical class 0.000 description 14
• 239000008346 aqueous phase Substances 0.000 description 14
• 125000005842 heteroatom Chemical group 0.000 description 14
• 239000003921 oil Substances 0.000 description 14
• 235000019198 oils Nutrition 0.000 description 14
• 229910052760 oxygen Inorganic materials 0.000 description 14
• 238000005481 NMR spectroscopy Methods 0.000 description 13
• 125000001309 chloro group Chemical group Cl* 0.000 description 13
• 235000019000 fluorine Nutrition 0.000 description 13
• 208000004296 neuralgia Diseases 0.000 description 13
• 208000021722 neuropathic pain Diseases 0.000 description 13
• 208000011580 syndromic disease Diseases 0.000 description 13
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
• 238000003756 stirring Methods 0.000 description 12
• 208000006820 Arthralgia Diseases 0.000 description 11
• 208000004454 Hyperalgesia Diseases 0.000 description 11
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
• 239000001301 oxygen Substances 0.000 description 11
• ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 10
• 125000001246 bromo group Chemical group Br* 0.000 description 10
• 238000001816 cooling Methods 0.000 description 10
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 10
• 201000008482 osteoarthritis Diseases 0.000 description 10
• 239000008194 pharmaceutical composition Substances 0.000 description 10
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
• 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 description 9
• 206010020751 Hypersensitivity Diseases 0.000 description 9
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
• 230000009467 reduction Effects 0.000 description 9
• 238000006722 reduction reaction Methods 0.000 description 9
• ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 8
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 8
• 208000035154 Hyperesthesia Diseases 0.000 description 8
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 8
• 230000001154 acute effect Effects 0.000 description 8
• 125000004429 atom Chemical group 0.000 description 8
• 230000001419 dependent effect Effects 0.000 description 8
• CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 8
• BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 8
• 125000005843 halogen group Chemical group 0.000 description 8
• 230000035807 sensation Effects 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 7
• JXFAAKRSQWLCQU-UHFFFAOYSA-N 5,7-dichloro-2,3-dihydro-1h-inden-1-amine Chemical compound ClC1=CC(Cl)=C2C(N)CCC2=C1 JXFAAKRSQWLCQU-UHFFFAOYSA-N 0.000 description 7
• 201000002481 Myositis Diseases 0.000 description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
• 208000036142 Viral infection Diseases 0.000 description 7
• 208000006673 asthma Diseases 0.000 description 7
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 7
• 239000003054 catalyst Substances 0.000 description 7
• 239000003480 eluent Substances 0.000 description 7
• 239000000706 filtrate Substances 0.000 description 7
• 208000014674 injury Diseases 0.000 description 7
• 125000002950 monocyclic group Chemical group 0.000 description 7
• 239000012074 organic phase Substances 0.000 description 7
• 125000006239 protecting group Chemical group 0.000 description 7
• 125000004076 pyridyl group Chemical group 0.000 description 7
• 206010039073 rheumatoid arthritis Diseases 0.000 description 7
• 239000007858 starting material Substances 0.000 description 7
• 201000005569 Gout Diseases 0.000 description 6
• 206010065390 Inflammatory pain Diseases 0.000 description 6
• 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 6
• 229910010082 LiAlH Inorganic materials 0.000 description 6
• BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 6
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 6
• 235000019502 Orange oil Nutrition 0.000 description 6
• 206010047115 Vasculitis Diseases 0.000 description 6
• 208000026935 allergic disease Diseases 0.000 description 6
• 230000009400 cancer invasion Effects 0.000 description 6
• 229910052799 carbon Inorganic materials 0.000 description 6
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 6
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
• 229940079593 drug Drugs 0.000 description 6
• 230000009610 hypersensitivity Effects 0.000 description 6
• 208000015181 infectious disease Diseases 0.000 description 6
• 208000002551 irritable bowel syndrome Diseases 0.000 description 6
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
• 125000004433 nitrogen atom Chemical group N* 0.000 description 6
• 239000010502 orange oil Substances 0.000 description 6
• 230000008058 pain sensation Effects 0.000 description 6
• 125000000714 pyrimidinyl group Chemical group 0.000 description 6
• 102000005962 receptors Human genes 0.000 description 6
• 108020003175 receptors Proteins 0.000 description 6
• 238000010992 reflux Methods 0.000 description 6
• 230000035945 sensitivity Effects 0.000 description 6
• 229910052717 sulfur Chemical group 0.000 description 6
• 230000008733 trauma Effects 0.000 description 6
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
• 230000009385 viral infection Effects 0.000 description 6
• OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 5
• 208000003456 Juvenile Arthritis Diseases 0.000 description 5
• 239000007868 Raney catalyst Substances 0.000 description 5
• NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 5
• 229910000564 Raney nickel Inorganic materials 0.000 description 5
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 5
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
• 230000002159 abnormal effect Effects 0.000 description 5
• 239000005557 antagonist Substances 0.000 description 5
• 239000007864 aqueous solution Substances 0.000 description 5
• 206010003246 arthritis Diseases 0.000 description 5
• 150000001721 carbon Chemical group 0.000 description 5
• 239000003638 chemical reducing agent Substances 0.000 description 5
• 238000005859 coupling reaction Methods 0.000 description 5
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 5
• 150000002148 esters Chemical class 0.000 description 5
• 125000002541 furyl group Chemical group 0.000 description 5
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 5
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
• 201000006417 multiple sclerosis Diseases 0.000 description 5
• 125000001715 oxadiazolyl group Chemical group 0.000 description 5
• 125000003386 piperidinyl group Chemical group 0.000 description 5
• 201000003068 rheumatic fever Diseases 0.000 description 5
• 206010039083 rhinitis Diseases 0.000 description 5
• 238000000926 separation method Methods 0.000 description 5
• 230000000638 stimulation Effects 0.000 description 5
• 239000011593 sulfur Chemical group 0.000 description 5
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
• 206010044652 trigeminal neuralgia Diseases 0.000 description 5
• 239000003643 water by type Substances 0.000 description 5
• 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 4
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
• BDWHVFDZURHALZ-UHFFFAOYSA-N 2,3-dihydrofuro[2,3-b]pyridine-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)COC2=N1 BDWHVFDZURHALZ-UHFFFAOYSA-N 0.000 description 4
• MIIUTVAPZUZUNH-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-2-[4-(trifluoromethyl)phenyl]ethanamine Chemical compound C=1C=C(C(F)(F)F)C=CC=1C(CN)N1CCC(F)(F)CC1 MIIUTVAPZUZUNH-UHFFFAOYSA-N 0.000 description 4
• 206010002556 Ankylosing Spondylitis Diseases 0.000 description 4
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
• 208000000094 Chronic Pain Diseases 0.000 description 4
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 4
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 4
• 208000011231 Crohn disease Diseases 0.000 description 4
• 201000004624 Dermatitis Diseases 0.000 description 4
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
• 208000007465 Giant cell arteritis Diseases 0.000 description 4
• 208000019695 Migraine disease Diseases 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000004913 activation Effects 0.000 description 4
• 125000003342 alkenyl group Chemical group 0.000 description 4
• 125000004849 alkoxymethyl group Chemical group 0.000 description 4
• 210000003169 central nervous system Anatomy 0.000 description 4
• 208000019425 cirrhosis of liver Diseases 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
• 201000003146 cystitis Diseases 0.000 description 4
• 230000000694 effects Effects 0.000 description 4
• 238000010438 heat treatment Methods 0.000 description 4
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 4
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical group I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
• 238000005984 hydrogenation reaction Methods 0.000 description 4
• 125000002883 imidazolyl group Chemical group 0.000 description 4
• 230000002458 infectious effect Effects 0.000 description 4
• 208000027866 inflammatory disease Diseases 0.000 description 4
• 125000001786 isothiazolyl group Chemical group 0.000 description 4
• 150000002576 ketones Chemical class 0.000 description 4
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
• 206010027599 migraine Diseases 0.000 description 4
• 125000002757 morpholinyl group Chemical group 0.000 description 4
• RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 4
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
• 125000002971 oxazolyl group Chemical group 0.000 description 4
• 150000002923 oximes Chemical class 0.000 description 4
• 239000012071 phase Substances 0.000 description 4
• 239000002953 phosphate buffered saline Substances 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 125000003373 pyrazinyl group Chemical group 0.000 description 4
• 125000003226 pyrazolyl group Chemical group 0.000 description 4
• 125000002098 pyridazinyl group Chemical group 0.000 description 4
• 125000000168 pyrrolyl group Chemical group 0.000 description 4
• 201000005671 spondyloarthropathy Diseases 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• 239000000725 suspension Substances 0.000 description 4
• 206010043207 temporal arteritis Diseases 0.000 description 4
• 125000001113 thiadiazolyl group Chemical group 0.000 description 4
• 125000000335 thiazolyl group Chemical group 0.000 description 4
• 125000001544 thienyl group Chemical group 0.000 description 4
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
• 125000001425 triazolyl group Chemical group 0.000 description 4
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
• JRHZPIQUOBZXQO-UHFFFAOYSA-N 1,2-dichloro-2,3-dihydroinden-1-amine Chemical compound ClC1C(C2=CC=CC=C2C1)(N)Cl JRHZPIQUOBZXQO-UHFFFAOYSA-N 0.000 description 3
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
• GQIJZHQOINPPCW-UHFFFAOYSA-N 3,4-dihydro-2h-pyrano[2,3-b]pyridine-4-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)CCOC2=N1 GQIJZHQOINPPCW-UHFFFAOYSA-N 0.000 description 3
• IDGFAFHWGOCKOW-UHFFFAOYSA-N 3-(aminomethyl)-2-chlorobenzonitrile Chemical compound NCC1=CC=CC(C#N)=C1Cl IDGFAFHWGOCKOW-UHFFFAOYSA-N 0.000 description 3
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
• 208000024827 Alzheimer disease Diseases 0.000 description 3
• 208000008035 Back Pain Diseases 0.000 description 3
• 206010006002 Bone pain Diseases 0.000 description 3
• 206010009900 Colitis ulcerative Diseases 0.000 description 3
• 206010011224 Cough Diseases 0.000 description 3
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 3
• 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
• 208000005171 Dysmenorrhea Diseases 0.000 description 3
• 206010013935 Dysmenorrhoea Diseases 0.000 description 3
• 206010014561 Emphysema Diseases 0.000 description 3
• 208000001640 Fibromyalgia Diseases 0.000 description 3
• 206010016654 Fibrosis Diseases 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• 206010018364 Glomerulonephritis Diseases 0.000 description 3
• 206010018634 Gouty Arthritis Diseases 0.000 description 3
• 208000023105 Huntington disease Diseases 0.000 description 3
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
• 206010061218 Inflammation Diseases 0.000 description 3
• 208000003250 Mixed connective tissue disease Diseases 0.000 description 3
• 206010028391 Musculoskeletal Pain Diseases 0.000 description 3
• 206010028836 Neck pain Diseases 0.000 description 3
• 206010062501 Non-cardiac chest pain Diseases 0.000 description 3
• 208000001132 Osteoporosis Diseases 0.000 description 3
• 206010036376 Postherpetic Neuralgia Diseases 0.000 description 3
• 208000004550 Postoperative Pain Diseases 0.000 description 3
• 201000004681 Psoriasis Diseases 0.000 description 3
• 208000008765 Sciatica Diseases 0.000 description 3
• 208000010040 Sprains and Strains Diseases 0.000 description 3
• DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
• 206010064390 Tumour invasion Diseases 0.000 description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 description 3
• ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 3
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
• SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 3
• 208000005298 acute pain Diseases 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 150000001299 aldehydes Chemical class 0.000 description 3
• 239000002168 alkylating agent Substances 0.000 description 3
• 229940100198 alkylating agent Drugs 0.000 description 3
• 206010053552 allodynia Diseases 0.000 description 3
• 238000002266 amputation Methods 0.000 description 3
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
• 239000012298 atmosphere Substances 0.000 description 3
• 201000008937 atopic dermatitis Diseases 0.000 description 3
• 239000003153 chemical reaction reagent Substances 0.000 description 3
• 238000002512 chemotherapy Methods 0.000 description 3
• 239000012230 colorless oil Substances 0.000 description 3
• 239000002299 complementary DNA Substances 0.000 description 3
• 125000004122 cyclic group Chemical group 0.000 description 3
• WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 3
• 230000007850 degeneration Effects 0.000 description 3
• 229910052805 deuterium Inorganic materials 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
• 239000002158 endotoxin Substances 0.000 description 3
• PAVZHTXVORCEHP-UHFFFAOYSA-N ethylboronic acid Chemical compound CCB(O)O PAVZHTXVORCEHP-UHFFFAOYSA-N 0.000 description 3
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
• 230000004761 fibrosis Effects 0.000 description 3
• 235000019253 formic acid Nutrition 0.000 description 3
• 230000004968 inflammatory condition Effects 0.000 description 3
• 230000004054 inflammatory process Effects 0.000 description 3
• 206010022000 influenza Diseases 0.000 description 3
• 125000002346 iodo group Chemical group I* 0.000 description 3
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
• 125000000842 isoxazolyl group Chemical group 0.000 description 3
• 229920006008 lipopolysaccharide Polymers 0.000 description 3
• 210000004072 lung Anatomy 0.000 description 3
• 238000005259 measurement Methods 0.000 description 3
• 239000002609 medium Substances 0.000 description 3
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
• 208000031225 myocardial ischemia Diseases 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
• 125000001624 naphthyl group Chemical group 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 201000001119 neuropathy Diseases 0.000 description 3
• 230000007823 neuropathy Effects 0.000 description 3
• 201000001245 periodontitis Diseases 0.000 description 3
• 208000033808 peripheral neuropathy Diseases 0.000 description 3
• 208000030062 persistent idiopathic facial pain Diseases 0.000 description 3
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 210000001525 retina Anatomy 0.000 description 3
• 201000000306 sarcoidosis Diseases 0.000 description 3
• 230000001953 sensory effect Effects 0.000 description 3
• 230000009155 sensory pathway Effects 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 208000020431 spinal cord injury Diseases 0.000 description 3
• 230000003068 static effect Effects 0.000 description 3
• 239000000126 substance Substances 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 230000002889 sympathetic effect Effects 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• 208000004371 toothache Diseases 0.000 description 3
• 239000003053 toxin Substances 0.000 description 3
• 231100000765 toxin Toxicity 0.000 description 3
• 108700012359 toxins Proteins 0.000 description 3
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
• LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 3
• 201000008827 tuberculosis Diseases 0.000 description 3
• 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
• PJQHBIZKIZNKFP-UHFFFAOYSA-N (2,4-dichloro-6-cyclopropylphenyl)methanamine Chemical compound NCC1=C(Cl)C=C(Cl)C=C1C1CC1 PJQHBIZKIZNKFP-UHFFFAOYSA-N 0.000 description 2
• MAZXZNBJSFOCQS-UHFFFAOYSA-N (2,4-dichloro-6-ethylphenyl)methanamine Chemical compound CCC1=CC(Cl)=CC(Cl)=C1CN MAZXZNBJSFOCQS-UHFFFAOYSA-N 0.000 description 2
• CVABMJFTRNSEOP-UHFFFAOYSA-N (2,4-dichloro-6-methoxyphenyl)methanamine Chemical compound COC1=CC(Cl)=CC(Cl)=C1CN CVABMJFTRNSEOP-UHFFFAOYSA-N 0.000 description 2
• 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
• 125000006704 (C5-C6) cycloalkyl group Chemical group 0.000 description 2
• IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
• 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 2
• GNHGSSSQCHAIEL-UHFFFAOYSA-N 1h-azepine;hydrobromide Chemical compound Br.N1C=CC=CC=C1 GNHGSSSQCHAIEL-UHFFFAOYSA-N 0.000 description 2
• PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
• XFYKHXQQNRESHU-UHFFFAOYSA-N 2,4-dichloro-6-hydroxybenzaldehyde Chemical compound OC1=CC(Cl)=CC(Cl)=C1C=O XFYKHXQQNRESHU-UHFFFAOYSA-N 0.000 description 2
• LEKBRTWDQNPRPZ-UHFFFAOYSA-N 2,4-dichloro-6-methoxybenzaldehyde Chemical compound COC1=CC(Cl)=CC(Cl)=C1C=O LEKBRTWDQNPRPZ-UHFFFAOYSA-N 0.000 description 2
• 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 2
• NHWSEUMAGVQQQQ-UHFFFAOYSA-N 2-[2-(aminomethyl)-3,5-dichlorophenoxy]ethanol Chemical compound NCC1=C(Cl)C=C(Cl)C=C1OCCO NHWSEUMAGVQQQQ-UHFFFAOYSA-N 0.000 description 2
• NIGNBEIOCCTISO-UHFFFAOYSA-N 2-[3,5-dichloro-2-(hydroxyiminomethyl)phenoxy]ethyl acetate Chemical compound CC(=O)OCCOC1=CC(Cl)=CC(Cl)=C1C=NO NIGNBEIOCCTISO-UHFFFAOYSA-N 0.000 description 2
• QLYGWNMFYAQPEN-UHFFFAOYSA-N 2-[[2-(aminomethyl)-3,5-dichlorophenyl]methoxy]ethanol Chemical compound NCC1=C(Cl)C=C(Cl)C=C1COCCO QLYGWNMFYAQPEN-UHFFFAOYSA-N 0.000 description 2
• MDEHBAMASAXISQ-UHFFFAOYSA-N 2-amino-2-cycloheptylethanol Chemical compound OCC(N)C1CCCCCC1 MDEHBAMASAXISQ-UHFFFAOYSA-N 0.000 description 2
• XQGWCOLVXPDNLK-UHFFFAOYSA-N 2-amino-5,7-dichloro-2,3-dihydroinden-1-one Chemical compound ClC1=CC(Cl)=C2C(=O)C(N)CC2=C1 XQGWCOLVXPDNLK-UHFFFAOYSA-N 0.000 description 2
• BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
• 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 description 2
• VXFMNHKLXSDLKL-UHFFFAOYSA-N 3,4-dihydro-2h-pyrano[2,3-b]pyridine Chemical compound C1=CC=C2CCCOC2=N1 VXFMNHKLXSDLKL-UHFFFAOYSA-N 0.000 description 2
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
• OABUKBBBSMNNPM-UHFFFAOYSA-N 4,4-difluoropiperidin-1-ium;chloride Chemical compound Cl.FC1(F)CCNCC1 OABUKBBBSMNNPM-UHFFFAOYSA-N 0.000 description 2
• 208000030507 AIDS Diseases 0.000 description 2
• 206010033646 Acute and chronic pancreatitis Diseases 0.000 description 2
• 208000026872 Addison Disease Diseases 0.000 description 2
• ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 2
• 208000035939 Alveolitis allergic Diseases 0.000 description 2
• 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 2
• 208000019901 Anxiety disease Diseases 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 201000001320 Atherosclerosis Diseases 0.000 description 2
• 208000023328 Basedow disease Diseases 0.000 description 2
• 208000009137 Behcet syndrome Diseases 0.000 description 2
• 208000002691 Choroiditis Diseases 0.000 description 2
• 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 2
• 208000006561 Cluster Headache Diseases 0.000 description 2
• 208000034656 Contusions Diseases 0.000 description 2
• 229910021591 Copper(I) chloride Inorganic materials 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 206010012438 Dermatitis atopic Diseases 0.000 description 2
• 206010012442 Dermatitis contact Diseases 0.000 description 2
• 208000006926 Discoid Lupus Erythematosus Diseases 0.000 description 2
• 206010053776 Eosinophilic cellulitis Diseases 0.000 description 2
• 206010014954 Eosinophilic fasciitis Diseases 0.000 description 2
• 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 2
• 208000027445 Farmer Lung Diseases 0.000 description 2
• 206010017533 Fungal infection Diseases 0.000 description 2
• 206010061459 Gastrointestinal ulcer Diseases 0.000 description 2
• 208000015023 Graves' disease Diseases 0.000 description 2
• 239000007821 HATU Substances 0.000 description 2
• 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
• 206010019233 Headaches Diseases 0.000 description 2
• OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
• 206010061246 Intervertebral disc degeneration Diseases 0.000 description 2
• 208000009829 Lewy Body Disease Diseases 0.000 description 2
• 201000002832 Lewy body dementia Diseases 0.000 description 2
• 208000000185 Localized scleroderma Diseases 0.000 description 2
• 201000009906 Meningitis Diseases 0.000 description 2
• GMPKIPWJBDOURN-UHFFFAOYSA-N Methoxyamine Chemical compound CON GMPKIPWJBDOURN-UHFFFAOYSA-N 0.000 description 2
• 208000021642 Muscular disease Diseases 0.000 description 2
• 208000000112 Myalgia Diseases 0.000 description 2
• 208000031888 Mycoses Diseases 0.000 description 2
• 201000009623 Myopathy Diseases 0.000 description 2
• MBJNTVURQKKJTG-UHFFFAOYSA-N N-[(2,4-dichloro-6-methoxyphenyl)methylidene]hydroxylamine Chemical compound COc1cc(Cl)cc(Cl)c1C=NO MBJNTVURQKKJTG-UHFFFAOYSA-N 0.000 description 2
• 206010029164 Nephrotic syndrome Diseases 0.000 description 2
• 241001420836 Ophthalmitis Species 0.000 description 2
• 208000010191 Osteitis Deformans Diseases 0.000 description 2
• 206010031264 Osteonecrosis Diseases 0.000 description 2
• 208000027868 Paget disease Diseases 0.000 description 2
• 208000018737 Parkinson disease Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• 206010065159 Polychondritis Diseases 0.000 description 2
• 208000003971 Posterior uveitis Diseases 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 208000021386 Sjogren Syndrome Diseases 0.000 description 2
• 206010041591 Spinal osteoarthritis Diseases 0.000 description 2
• 238000006069 Suzuki reaction reaction Methods 0.000 description 2
• 201000009594 Systemic Scleroderma Diseases 0.000 description 2
• 206010042953 Systemic sclerosis Diseases 0.000 description 2
• 208000001106 Takayasu Arteritis Diseases 0.000 description 2
• 208000000491 Tendinopathy Diseases 0.000 description 2
• 206010043255 Tendonitis Diseases 0.000 description 2
• 206010043269 Tension headache Diseases 0.000 description 2
• 208000008548 Tension-Type Headache Diseases 0.000 description 2
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
• 208000007536 Thrombosis Diseases 0.000 description 2
• 208000025865 Ulcer Diseases 0.000 description 2
• 206010046996 Varicose vein Diseases 0.000 description 2
• 208000008526 Wells syndrome Diseases 0.000 description 2
• OBRMABLMXUZGRW-UHFFFAOYSA-N [2,4-dichloro-6-(methoxymethyl)phenyl]methanamine Chemical compound COCC1=CC(Cl)=CC(Cl)=C1CN OBRMABLMXUZGRW-UHFFFAOYSA-N 0.000 description 2
• PGXFINRTEQIZDQ-UHFFFAOYSA-N [2-(aminomethyl)-3,5-dichlorophenyl]methanol Chemical compound NCC1=C(Cl)C=C(Cl)C=C1CO PGXFINRTEQIZDQ-UHFFFAOYSA-N 0.000 description 2
• RJMISNVORNXHIZ-UHFFFAOYSA-N [2-(aminomethyl)-3-chlorophenyl]methanol Chemical compound NCC1=C(Cl)C=CC=C1CO RJMISNVORNXHIZ-UHFFFAOYSA-N 0.000 description 2
• 150000007960 acetonitrile Chemical class 0.000 description 2
• 229960001456 adenosine triphosphate Drugs 0.000 description 2
• 238000005804 alkylation reaction Methods 0.000 description 2
• 206010002022 amyloidosis Diseases 0.000 description 2
• 201000004984 autoimmune cardiomyopathy Diseases 0.000 description 2
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000001185 bone marrow Anatomy 0.000 description 2
• 208000024883 bone remodeling disease Diseases 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• 206010006451 bronchitis Diseases 0.000 description 2
• HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Chemical compound [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 239000003795 chemical substances by application Substances 0.000 description 2
• 201000001352 cholecystitis Diseases 0.000 description 2
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
• 230000007882 cirrhosis Effects 0.000 description 2
• 208000018912 cluster headache syndrome Diseases 0.000 description 2
• 206010009887 colitis Diseases 0.000 description 2
• 208000010247 contact dermatitis Diseases 0.000 description 2
• 230000009519 contusion Effects 0.000 description 2
• OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 2
• 208000037329 crystal arthropathy Diseases 0.000 description 2
• 208000004921 cutaneous lupus erythematosus Diseases 0.000 description 2
• 238000007333 cyanation reaction Methods 0.000 description 2
• 238000006352 cycloaddition reaction Methods 0.000 description 2
• 201000001981 dermatomyositis Diseases 0.000 description 2
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
• 125000000532 dioxanyl group Chemical group 0.000 description 2
• 208000037765 diseases and disorders Diseases 0.000 description 2
• 238000000105 evaporative light scattering detection Methods 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 208000022195 farmer lung disease Diseases 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 239000007789 gas Substances 0.000 description 2
• 238000007429 general method Methods 0.000 description 2
• 150000004820 halides Chemical class 0.000 description 2
• 231100000869 headache Toxicity 0.000 description 2
• NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
• 150000003840 hydrochlorides Chemical class 0.000 description 2
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
• 125000002632 imidazolidinyl group Chemical group 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 201000006334 interstitial nephritis Diseases 0.000 description 2
• 230000001057 ionotropic effect Effects 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 239000010410 layer Substances 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 208000027202 mammary Paget disease Diseases 0.000 description 2
• 108020004999 messenger RNA Proteins 0.000 description 2
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
• QNPDGOKVPWQSPA-UHFFFAOYSA-N methyl 2-[2,4-dichloro-6-(trifluoromethyl)phenyl]acetate Chemical compound COC(=O)CC1=C(Cl)C=C(Cl)C=C1C(F)(F)F QNPDGOKVPWQSPA-UHFFFAOYSA-N 0.000 description 2
• 230000011987 methylation Effects 0.000 description 2
• 238000007069 methylation reaction Methods 0.000 description 2
• 206010063344 microscopic polyangiitis Diseases 0.000 description 2
• 210000005087 mononuclear cell Anatomy 0.000 description 2
• 230000036651 mood Effects 0.000 description 2
• 230000003387 muscular Effects 0.000 description 2
• 206010028417 myasthenia gravis Diseases 0.000 description 2
• 201000009240 nasopharyngitis Diseases 0.000 description 2
• 201000008383 nephritis Diseases 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000003040 nociceptive effect Effects 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• 125000000160 oxazolidinyl group Chemical group 0.000 description 2
• 230000001590 oxidative effect Effects 0.000 description 2
• 229910052763 palladium Inorganic materials 0.000 description 2
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
• 208000010403 panophthalmitis Diseases 0.000 description 2
• 208000012111 paraneoplastic syndrome Diseases 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• 208000028169 periodontal disease Diseases 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• 125000005543 phthalimide group Chemical group 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• 239000013612 plasmid Substances 0.000 description 2
• 208000005987 polymyositis Diseases 0.000 description 2
• 239000002244 precipitate Substances 0.000 description 2
• 238000002360 preparation method Methods 0.000 description 2
• 208000005069 pulmonary fibrosis Diseases 0.000 description 2
• 238000010926 purge Methods 0.000 description 2
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 2
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
• 230000003248 secreting effect Effects 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 2
• 210000002784 stomach Anatomy 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 125000004434 sulfur atom Chemical group 0.000 description 2
• 230000009885 systemic effect Effects 0.000 description 2
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
• 210000001738 temporomandibular joint Anatomy 0.000 description 2
• 201000004415 tendinitis Diseases 0.000 description 2
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• ZTQUQGRSCLFRFM-UHFFFAOYSA-N tert-butyl 2-amino-2-cycloheptylacetate Chemical compound CC(C)(C)OC(=O)C(N)C1CCCCCC1 ZTQUQGRSCLFRFM-UHFFFAOYSA-N 0.000 description 2
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
• 125000001984 thiazolidinyl group Chemical group 0.000 description 2
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• KTMKRRPZPWUYKK-FIBGUPNXSA-N trideuteriomethylboronic acid Chemical compound [2H]C([2H])([2H])B(O)O KTMKRRPZPWUYKK-FIBGUPNXSA-N 0.000 description 2
• 208000027185 varicose disease Diseases 0.000 description 2
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
• VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
• IBKDNYJEYFQCER-UHFFFAOYSA-N (2,4,6-trichlorophenyl)methanamine Chemical compound NCC1=C(Cl)C=C(Cl)C=C1Cl IBKDNYJEYFQCER-UHFFFAOYSA-N 0.000 description 1
• LJCWDBOQZQKUHR-UHFFFAOYSA-N (2,4-dichloro-6-ethenylphenyl)methanamine Chemical compound NCC1=C(Cl)C=C(Cl)C=C1C=C LJCWDBOQZQKUHR-UHFFFAOYSA-N 0.000 description 1
• QPZDTJTYUUNPBC-UHFFFAOYSA-N (2,4-dichloro-6-fluorophenyl)methanamine Chemical compound NCC1=C(F)C=C(Cl)C=C1Cl QPZDTJTYUUNPBC-UHFFFAOYSA-N 0.000 description 1
• QISTWSMZJRTDCS-UHFFFAOYSA-N (2,4-dichloro-6-methylphenyl)methanamine Chemical compound CC1=CC(Cl)=CC(Cl)=C1CN QISTWSMZJRTDCS-UHFFFAOYSA-N 0.000 description 1
• RJKAZUSMXMBSLM-UHFFFAOYSA-N (2-bromo-4,6-dichlorophenyl)methanamine Chemical compound NCC1=C(Cl)C=C(Cl)C=C1Br RJKAZUSMXMBSLM-UHFFFAOYSA-N 0.000 description 1
• VWMOCFARWTYBNT-MRVPVSSYSA-N (2S)-2-amino-2-(2,4-dichlorophenyl)ethanol Chemical compound OC[C@@H](N)C1=CC=C(Cl)C=C1Cl VWMOCFARWTYBNT-MRVPVSSYSA-N 0.000 description 1
• DAJHPAKSBGHTKL-GJZGRUSLSA-N (3R)-N-[(1R)-1-cycloheptyl-2-hydroxyethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1(CCCCCC1)[C@H](CO)NC(=O)[C@H]1COC2=NC=CC=C21 DAJHPAKSBGHTKL-GJZGRUSLSA-N 0.000 description 1
• NFOIXXSQPSBYPD-LSDHHAIUSA-N (3R)-N-[(1R)-5-chloro-2,3-dihydro-1H-inden-1-yl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC=1C=C2CC[C@H](C2=CC1)NC(=O)[C@H]1COC2=NC=CC=C21 NFOIXXSQPSBYPD-LSDHHAIUSA-N 0.000 description 1
• NZCFDDMETPJUAL-JSGCOSHPSA-N (3R)-N-[(1S)-7-bromo-2,3-dihydro-1H-inden-1-yl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound Brc1cccc2CC[C@H](NC(=O)[C@H]3COc4ncccc34)c12 NZCFDDMETPJUAL-JSGCOSHPSA-N 0.000 description 1
• WKQXOBVXZVHDBY-LSDHHAIUSA-N (3R)-N-[(2S)-2-(4,4-difluoropiperidin-1-yl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound FC1(CCN(CC1)[C@H](CNC(=O)[C@H]1COC2=NC=CC=C21)C=2C=NC(=NC2)C(F)(F)F)F WKQXOBVXZVHDBY-LSDHHAIUSA-N 0.000 description 1
• NZCFDDMETPJUAL-TZMCWYRMSA-N (3S)-N-[(1R)-7-bromo-2,3-dihydro-1H-inden-1-yl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound Brc1cccc2CC[C@@H](NC(=O)[C@@H]3COc4ncccc34)c12 NZCFDDMETPJUAL-TZMCWYRMSA-N 0.000 description 1
• NZCFDDMETPJUAL-OCCSQVGLSA-N (3S)-N-[(1S)-7-bromo-2,3-dihydro-1H-inden-1-yl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound Brc1cccc2CC[C@H](NC(=O)[C@@H]3COc4ncccc34)c12 NZCFDDMETPJUAL-OCCSQVGLSA-N 0.000 description 1
• WKQXOBVXZVHDBY-CABCVRRESA-N (3S)-N-[(2R)-2-(4,4-difluoropiperidin-1-yl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound FC1(CCN(CC1)[C@@H](CNC(=O)[C@@H]1COC2=NC=CC=C21)C=2C=NC(=NC2)C(F)(F)F)F WKQXOBVXZVHDBY-CABCVRRESA-N 0.000 description 1
• CZPLKOIQGWGITH-NSHDSACASA-N (3r)-n-[(2,4,6-trichlorophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC(Cl)=C1CNC(=O)[C@@H]1C2=CC=CN=C2OC1 CZPLKOIQGWGITH-NSHDSACASA-N 0.000 description 1
• GOCMKLPZAAFVSY-NOZJJQNGSA-N (3s)-n-[(1r)-1-(2,4-dichlorophenyl)ethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical compound C1([C@H](NC(=O)[C@H]2C3=CC=CN=C3OC2)C)=CC=C(Cl)C=C1Cl GOCMKLPZAAFVSY-NOZJJQNGSA-N 0.000 description 1
• DAJHPAKSBGHTKL-HUUCEWRRSA-N (3s)-n-[(1s)-1-cycloheptyl-2-hydroxyethyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical group C1([C@H](NC(=O)[C@H]2C3=CC=CN=C3OC2)CO)CCCCCC1 DAJHPAKSBGHTKL-HUUCEWRRSA-N 0.000 description 1
• NFOIXXSQPSBYPD-CABCVRRESA-N (3s)-n-[(1s)-5-chloro-2,3-dihydro-1h-inden-1-yl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical group C1OC2=NC=CC=C2[C@@H]1C(=O)N[C@@H]1C2=CC=C(Cl)C=C2CC1 NFOIXXSQPSBYPD-CABCVRRESA-N 0.000 description 1
• CZPLKOIQGWGITH-LLVKDONJSA-N (3s)-n-[(2,4,6-trichlorophenyl)methyl]-2,3-dihydrofuro[2,3-b]pyridine-3-carboxamide Chemical group ClC1=CC(Cl)=CC(Cl)=C1CNC(=O)[C@H]1C2=CC=CN=C2OC1 CZPLKOIQGWGITH-LLVKDONJSA-N 0.000 description 1
• GACLCUGVJCORSZ-IAQYHMDHSA-N (4R)-N-[(1S)-1-(2,4-dichlorophenyl)-2-hydroxyethyl]-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](CO)NC(=O)[C@@H]1CCOC2=NC=CC=C21 GACLCUGVJCORSZ-IAQYHMDHSA-N 0.000 description 1
• GACLCUGVJCORSZ-XHDPSFHLSA-N (4S)-N-[(1S)-1-(2,4-dichlorophenyl)-2-hydroxyethyl]-3,4-dihydro-2H-pyrano[2,3-b]pyridine-4-carboxamide Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](CO)NC(=O)[C@H]1CCOC2=NC=CC=C21 GACLCUGVJCORSZ-XHDPSFHLSA-N 0.000 description 1
• LGXVIGDEPROXKC-UHFFFAOYSA-N 1,1-dichloroethene Chemical group ClC(Cl)=C LGXVIGDEPROXKC-UHFFFAOYSA-N 0.000 description 1
• VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 1
• ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
• IBODDUNKEPPBKW-UHFFFAOYSA-N 1,5-dibromopentane Chemical compound BrCCCCCBr IBODDUNKEPPBKW-UHFFFAOYSA-N 0.000 description 1
• OZCNEACBSLUSER-UHFFFAOYSA-N 1-bromo-2-(bromomethyl)-3,5-dichlorobenzene Chemical compound ClC1=CC(Cl)=C(CBr)C(Br)=C1 OZCNEACBSLUSER-UHFFFAOYSA-N 0.000 description 1
• MICMHFIQSAMEJG-UHFFFAOYSA-N 1-bromopyrrolidine-2,5-dione Chemical compound BrN1C(=O)CCC1=O.BrN1C(=O)CCC1=O MICMHFIQSAMEJG-UHFFFAOYSA-N 0.000 description 1
• DRFZWZZCMLHZDO-UHFFFAOYSA-N 1-chloro-3-methyl-2-(trifluoromethyl)benzene Chemical group CC1=CC=CC(Cl)=C1C(F)(F)F DRFZWZZCMLHZDO-UHFFFAOYSA-N 0.000 description 1
• JZUMPNUYDJBTNO-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 JZUMPNUYDJBTNO-UHFFFAOYSA-N 0.000 description 1
• JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
• 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
• 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
• IFMHNXABCSMTFF-UHFFFAOYSA-N 2,3-dihydrofuro[2,3-b]pyridine Chemical compound C1=CN=C2OCCC2=C1 IFMHNXABCSMTFF-UHFFFAOYSA-N 0.000 description 1
• PJVQPPHJEYPUDB-UHFFFAOYSA-N 2,3-dihydrofuro[3,2-b]pyridine Chemical class C1=CC=C2OCCC2=N1 PJVQPPHJEYPUDB-UHFFFAOYSA-N 0.000 description 1
• PGODHCIOIPODFE-UHFFFAOYSA-N 2,4,6-trichlorobenzonitrile Chemical compound ClC1=CC(Cl)=C(C#N)C(Cl)=C1 PGODHCIOIPODFE-UHFFFAOYSA-N 0.000 description 1
• JMCUZGCEDLJQDE-UHFFFAOYSA-N 2,4-dichloro-6-(methoxymethyl)benzonitrile Chemical compound COCC1=CC(Cl)=CC(Cl)=C1C#N JMCUZGCEDLJQDE-UHFFFAOYSA-N 0.000 description 1
• OCJPQZFOBGQYEA-UHFFFAOYSA-N 2,4-dichloro-6-(trifluoromethyl)aniline Chemical compound NC1=C(Cl)C=C(Cl)C=C1C(F)(F)F OCJPQZFOBGQYEA-UHFFFAOYSA-N 0.000 description 1
• NFPYAMXNKNDVDS-UHFFFAOYSA-N 2,4-dichloro-6-methylbenzonitrile Chemical compound CC1=CC(Cl)=CC(Cl)=C1C#N NFPYAMXNKNDVDS-UHFFFAOYSA-N 0.000 description 1
• SIAPJUIDTOGEKO-UHFFFAOYSA-N 2-(3,5-dichloro-2-formylphenoxy)ethyl acetate Chemical compound CC(=O)OCCOC1=CC(Cl)=CC(Cl)=C1C=O SIAPJUIDTOGEKO-UHFFFAOYSA-N 0.000 description 1
• FWRVYWZXBFLYKA-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethanamine Chemical compound C=1N=C(C(F)(F)F)N=CC=1C(CN)N1CCC(F)(F)CC1 FWRVYWZXBFLYKA-UHFFFAOYSA-N 0.000 description 1
• IINMQJTYEAHPSO-UHFFFAOYSA-N 2-(bromomethyl)-4,6-dichlorobenzonitrile Chemical compound ClC1=CC(Cl)=C(C#N)C(CBr)=C1 IINMQJTYEAHPSO-UHFFFAOYSA-N 0.000 description 1
• MXVPDCXEOULWLU-UHFFFAOYSA-N 2-[(3,5-dichloro-2-cyanophenyl)methoxy]ethyl acetate Chemical compound CC(=O)OCCOCC1=CC(Cl)=CC(Cl)=C1C#N MXVPDCXEOULWLU-UHFFFAOYSA-N 0.000 description 1
• WRXHNKLAGLRFAS-UHFFFAOYSA-N 2-[2,4-dichloro-6-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=C(Cl)C=C(Cl)C=C1C(F)(F)F WRXHNKLAGLRFAS-UHFFFAOYSA-N 0.000 description 1
• SITHNMNGOHVILG-UHFFFAOYSA-N 2-bromo-3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1Br SITHNMNGOHVILG-UHFFFAOYSA-N 0.000 description 1
• RBHUDDGPJRWBTF-UHFFFAOYSA-N 2-chloro-3-methylbenzonitrile Chemical compound CC1=CC=CC(C#N)=C1Cl RBHUDDGPJRWBTF-UHFFFAOYSA-N 0.000 description 1
• KHPAGGHFIDLUMB-UHFFFAOYSA-N 2-chloropyridine-3-carbaldehyde Chemical compound ClC1=NC=CC=C1C=O KHPAGGHFIDLUMB-UHFFFAOYSA-N 0.000 description 1
• MESDALXDBSNYMH-UHFFFAOYSA-N 2-cyclopropylpyrimidine-5-carbaldehyde Chemical group N1=CC(C=O)=CN=C1C1CC1 MESDALXDBSNYMH-UHFFFAOYSA-N 0.000 description 1
• YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
• HXDLWJWIAHWIKI-UHFFFAOYSA-N 2-hydroxyethyl acetate Chemical compound CC(=O)OCCO HXDLWJWIAHWIKI-UHFFFAOYSA-N 0.000 description 1
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• ANPTUIJETQUQQQ-UHFFFAOYSA-N 2-morpholin-4-yl-2-[2-(trifluoromethyl)pyrimidin-5-yl]ethanamine Chemical compound C=1N=C(C(F)(F)F)N=CC=1C(CN)N1CCOCC1 ANPTUIJETQUQQQ-UHFFFAOYSA-N 0.000 description 1
• TWMGRMYPKAQCQH-UHFFFAOYSA-N 3-(bromomethyl)-2-chlorobenzonitrile Chemical compound ClC1=C(CBr)C=CC=C1C#N TWMGRMYPKAQCQH-UHFFFAOYSA-N 0.000 description 1
• FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
• INEMHABDFCKBID-UHFFFAOYSA-N 3-chloro-4-methylbenzonitrile Chemical group CC1=CC=C(C#N)C=C1Cl INEMHABDFCKBID-UHFFFAOYSA-N 0.000 description 1
• RRRCPCOJPQLWEP-UHFFFAOYSA-N 3-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CN=C2N(O)N=NC2=C1.C1=CN=C2N(O)N=NC2=C1 RRRCPCOJPQLWEP-UHFFFAOYSA-N 0.000 description 1
• BIGNWTAXBIQGAZ-UHFFFAOYSA-N 4,6-dichloro-2,3-dihydroinden-1-one Chemical group ClC1=CC(Cl)=CC2=C1CCC2=O BIGNWTAXBIQGAZ-UHFFFAOYSA-N 0.000 description 1
• BEOBZEOPTQQELP-UHFFFAOYSA-N 4-(trifluoromethyl)benzaldehyde Chemical group FC(F)(F)C1=CC=C(C=O)C=C1 BEOBZEOPTQQELP-UHFFFAOYSA-N 0.000 description 1
• JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
• 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
• MEDSHTHCZIOVPU-UHFFFAOYSA-N 5-chloro-2,3-dihydroinden-1-one Chemical group ClC1=CC=C2C(=O)CCC2=C1 MEDSHTHCZIOVPU-UHFFFAOYSA-N 0.000 description 1
• CTAIEPPAOULMFY-UHFFFAOYSA-N 6-methoxypyridine-3-carbaldehyde Chemical group COC1=CC=C(C=O)C=N1 CTAIEPPAOULMFY-UHFFFAOYSA-N 0.000 description 1
• ZWEODBMKCBWTTQ-UHFFFAOYSA-N 7-bromo-2,3-dihydroinden-1-one Chemical group BrC1=CC=CC2=C1C(=O)CC2 ZWEODBMKCBWTTQ-UHFFFAOYSA-N 0.000 description 1
• YNFZQNGHYQYLCF-UHFFFAOYSA-N 7-chloro-2,3-dihydroinden-1-one Chemical group ClC1=CC=CC2=C1C(=O)CC2 YNFZQNGHYQYLCF-UHFFFAOYSA-N 0.000 description 1
• CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
• 208000002874 Acne Vulgaris Diseases 0.000 description 1
• 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
• 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
• 201000004384 Alopecia Diseases 0.000 description 1
• 206010068172 Anal pruritus Diseases 0.000 description 1
• 208000028185 Angioedema Diseases 0.000 description 1
• 206010002921 Aortitis Diseases 0.000 description 1
• 206010053555 Arthritis bacterial Diseases 0.000 description 1
• 208000036487 Arthropathies Diseases 0.000 description 1
• 201000002909 Aspergillosis Diseases 0.000 description 1
• 208000036641 Aspergillus infections Diseases 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 206010056377 Bone tuberculosis Diseases 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• RVZAXFLLUKGWLE-UHFFFAOYSA-N BrC1=C(C(=CC(=C1)Cl)Cl)CBr.BrC1=C(CN2C(C3=CC=CC=C3C2=O)=O)C(=CC(=C1)Cl)Cl Chemical compound BrC1=C(C(=CC(=C1)Cl)Cl)CBr.BrC1=C(CN2C(C3=CC=CC=C3C2=O)=O)C(=CC(=C1)Cl)Cl RVZAXFLLUKGWLE-UHFFFAOYSA-N 0.000 description 1
• PJNCEPXBDDXGKN-UHFFFAOYSA-N BrC1=C(CN2C(C3=CC=CC=C3C2=O)=O)C(=CC(=C1)Cl)Cl.ClC1=C(CN)C(=CC(=C1)Cl)C1CC1 Chemical compound BrC1=C(CN2C(C3=CC=CC=C3C2=O)=O)C(=CC(=C1)Cl)Cl.ClC1=C(CN)C(=CC(=C1)Cl)C1CC1 PJNCEPXBDDXGKN-UHFFFAOYSA-N 0.000 description 1
• RHPXBMZKPIDMIK-UHFFFAOYSA-N BrC1=C(CN2C(C3=CC=CC=C3C2=O)=O)C(=CC(=C1)Cl)Cl.ClC1=C(CN)C(=CC(=C1)Cl)C=C Chemical compound BrC1=C(CN2C(C3=CC=CC=C3C2=O)=O)C(=CC(=C1)Cl)Cl.ClC1=C(CN)C(=CC(=C1)Cl)C=C RHPXBMZKPIDMIK-UHFFFAOYSA-N 0.000 description 1
• VFNOMJLXUPCSDA-UHFFFAOYSA-N BrCC1=C(C#N)C(=CC(=C1)Cl)Cl.C(C)(=O)O Chemical compound BrCC1=C(C#N)C(=CC(=C1)Cl)Cl.C(C)(=O)O VFNOMJLXUPCSDA-UHFFFAOYSA-N 0.000 description 1
• USVZVBGKPQGWOR-UHFFFAOYSA-N BrCC1=C(C#N)C(=CC(=C1)Cl)Cl.C(C)(=O)OCC1=C(C(=CC(=C1)Cl)Cl)C#N Chemical compound BrCC1=C(C#N)C(=CC(=C1)Cl)Cl.C(C)(=O)OCC1=C(C(=CC(=C1)Cl)Cl)C#N USVZVBGKPQGWOR-UHFFFAOYSA-N 0.000 description 1
• AILKYDYBCOZQPF-UHFFFAOYSA-N BrCC1=C(C#N)C(=CC(=C1)Cl)Cl.ClC1=C(C#N)C(=CC(=C1)Cl)COC Chemical compound BrCC1=C(C#N)C(=CC(=C1)Cl)Cl.ClC1=C(C#N)C(=CC(=C1)Cl)COC AILKYDYBCOZQPF-UHFFFAOYSA-N 0.000 description 1
• IOHGEFVDKTWJBH-UHFFFAOYSA-N BrCC=1C(=C(C#N)C=CC1)Cl.BrC1=C(CN)C(=CC(=C1)Cl)Cl Chemical compound BrCC=1C(=C(C#N)C=CC1)Cl.BrC1=C(CN)C(=CC(=C1)Cl)Cl IOHGEFVDKTWJBH-UHFFFAOYSA-N 0.000 description 1
• SGMNKZUFBBXEGU-UHFFFAOYSA-N BrCC=1C(=C(C#N)C=CC1)Cl.ClC1=C(CN)C=CC=C1C#N Chemical compound BrCC=1C(=C(C#N)C=CC1)Cl.ClC1=C(CN)C=CC=C1C#N SGMNKZUFBBXEGU-UHFFFAOYSA-N 0.000 description 1
• 208000003174 Brain Neoplasms Diseases 0.000 description 1
• BLMQQISSPMQOJE-UHFFFAOYSA-N C(C)(=O)OCC1=C(C(=CC(=C1)Cl)Cl)C#N.NCC1=C(C=C(C=C1Cl)Cl)CO Chemical compound C(C)(=O)OCC1=C(C(=CC(=C1)Cl)Cl)C#N.NCC1=C(C=C(C=C1Cl)Cl)CO BLMQQISSPMQOJE-UHFFFAOYSA-N 0.000 description 1
• MBQXOZUOJORLFL-UHFFFAOYSA-N C(C)OC(CC(O)C=1C(=NC=CC1)Cl)=O.ClC1=NC=CC=C1C(CCO)O Chemical compound C(C)OC(CC(O)C=1C(=NC=CC1)Cl)=O.ClC1=NC=CC=C1C(CCO)O MBQXOZUOJORLFL-UHFFFAOYSA-N 0.000 description 1
• UOMJIGSPTUCSTG-UHFFFAOYSA-N COC(=O)C1(F)COc2ncccc12 Chemical compound COC(=O)C1(F)COc2ncccc12 UOMJIGSPTUCSTG-UHFFFAOYSA-N 0.000 description 1
• SLTFOEHCTPRWLJ-UHFFFAOYSA-N COC(=O)C1=COC2=NC=CC=C21.COC(=O)C2COC1=NC=CC=C12 Chemical compound COC(=O)C1=COC2=NC=CC=C21.COC(=O)C2COC1=NC=CC=C12 SLTFOEHCTPRWLJ-UHFFFAOYSA-N 0.000 description 1
• PLMLVQVVGWAHDC-UHFFFAOYSA-N COC(=O)C1COC2=NC=CC=C21.O2CC(C=1C2=NC=CC1)C(=O)O Chemical compound COC(=O)C1COC2=NC=CC=C21.O2CC(C=1C2=NC=CC1)C(=O)O PLMLVQVVGWAHDC-UHFFFAOYSA-N 0.000 description 1
• BSVSUVMLKUANAJ-UHFFFAOYSA-N COC(=O)C1COc2ncccc12 Chemical compound COC(=O)C1COc2ncccc12 BSVSUVMLKUANAJ-UHFFFAOYSA-N 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• 206010007882 Cellulitis Diseases 0.000 description 1
• 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
• DROJCBMYHWMTCN-UHFFFAOYSA-N ClC1=C(C#N)C(=CC(=C1)Cl)F.ClC1=C(CN)C(=CC(=C1)Cl)F Chemical compound ClC1=C(C#N)C(=CC(=C1)Cl)F.ClC1=C(CN)C(=CC(=C1)Cl)F DROJCBMYHWMTCN-UHFFFAOYSA-N 0.000 description 1
• PDAUDCJHBUHHTH-UHFFFAOYSA-N ClC1=C(C#N)C=CC=C1C.ClC1=C(CN)C=CC(=C1)C#N Chemical compound ClC1=C(C#N)C=CC=C1C.ClC1=C(CN)C=CC(=C1)C#N PDAUDCJHBUHHTH-UHFFFAOYSA-N 0.000 description 1
• NDRIFVSHPQOGBS-UHFFFAOYSA-N ClC1=C(C#N)C=CC=C1C.FC(C1=C(CN)C=CC=C1Cl)(F)F Chemical compound ClC1=C(C#N)C=CC=C1C.FC(C1=C(CN)C=CC=C1Cl)(F)F NDRIFVSHPQOGBS-UHFFFAOYSA-N 0.000 description 1
• GYVHNDCUTONCRH-UHFFFAOYSA-N ClC1=C(C(=CC(=C1)Cl)C(F)(F)F)CC(=O)O.ClC1=C(CN)C(=CC(=C1)Cl)C(F)(F)F Chemical compound ClC1=C(C(=CC(=C1)Cl)C(F)(F)F)CC(=O)O.ClC1=C(CN)C(=CC(=C1)Cl)C(F)(F)F GYVHNDCUTONCRH-UHFFFAOYSA-N 0.000 description 1
• VFVOEGZESRPYMH-UHFFFAOYSA-N ClC1=C(C(=O)N)C(=CC(=C1)Cl)F.ClC1=C(C#N)C(=CC(=C1)Cl)F Chemical compound ClC1=C(C(=O)N)C(=CC(=C1)Cl)F.ClC1=C(C#N)C(=CC(=C1)Cl)F VFVOEGZESRPYMH-UHFFFAOYSA-N 0.000 description 1
• TXEBNCWNZYHMND-LLVKDONJSA-N ClC1=C(CNC(=O)[C@@H]2CCOC3=NC=CC=C32)C=CC=C1C(F)(F)F Chemical compound ClC1=C(CNC(=O)[C@@H]2CCOC3=NC=CC=C32)C=CC=C1C(F)(F)F TXEBNCWNZYHMND-LLVKDONJSA-N 0.000 description 1
• FEHIHBZGXMMYDJ-UHFFFAOYSA-N ClC1=NC=CC=C1C(CCO)O.O1CCC(C=2C1=NC=CC2)O Chemical compound ClC1=NC=CC=C1C(CCO)O.O1CCC(C=2C1=NC=CC2)O FEHIHBZGXMMYDJ-UHFFFAOYSA-N 0.000 description 1
• SYNWWPNXPFLVSW-UHFFFAOYSA-N ClC1CCOC2=NC=CC=C21.O2CCC(C=1C2=NC=CC1)C#N Chemical compound ClC1CCOC2=NC=CC=C21.O2CCC(C=1C2=NC=CC1)C#N SYNWWPNXPFLVSW-UHFFFAOYSA-N 0.000 description 1
• KQCZUUFHLKGSBQ-UHFFFAOYSA-N ClC=1C=C2CCC(C2=C(C1)Cl)=O.BrC=1C=CC=C2CCC(C12)N Chemical group ClC=1C=C2CCC(C2=C(C1)Cl)=O.BrC=1C=CC=C2CCC(C12)N KQCZUUFHLKGSBQ-UHFFFAOYSA-N 0.000 description 1
• MEHLIBOUOLHKAW-UHFFFAOYSA-N ClC=1C=C2CCC(C2=C(C1)Cl)=O.CON=C1CCC2=CC(=CC(=C12)Cl)Cl Chemical compound ClC=1C=C2CCC(C2=C(C1)Cl)=O.CON=C1CCC2=CC(=CC(=C12)Cl)Cl MEHLIBOUOLHKAW-UHFFFAOYSA-N 0.000 description 1
• BQRRFUNSPJSINI-UHFFFAOYSA-N ClC=1C=C2CCC(C2=C(C1)Cl)=O.ClC1=C2CCC(C2=CC(=C1)Cl)N Chemical group ClC=1C=C2CCC(C2=C(C1)Cl)=O.ClC1=C2CCC(C2=CC(=C1)Cl)N BQRRFUNSPJSINI-UHFFFAOYSA-N 0.000 description 1
• GPEDEDMOPBNMEZ-UHFFFAOYSA-N ClC=1C=C2CCC(C2=C(C1)Cl)=O.ClC=1C=C2CC(C(C2=C(C1)Cl)=O)=NO Chemical compound ClC=1C=C2CCC(C2=C(C1)Cl)=O.ClC=1C=C2CC(C(C2=C(C1)Cl)=O)=NO GPEDEDMOPBNMEZ-UHFFFAOYSA-N 0.000 description 1
• AUCCQLQYTAGVDH-UHFFFAOYSA-N ClC=1C=C2CCC(C2=C(C1)Cl)=O.ClC=1C=C2CCC(C2=CC1)N Chemical group ClC=1C=C2CCC(C2=C(C1)Cl)=O.ClC=1C=C2CCC(C2=CC1)N AUCCQLQYTAGVDH-UHFFFAOYSA-N 0.000 description 1
• DDLFFKOZDWUFOE-UHFFFAOYSA-N ClC=1C=C2CCC(C2=C(C1)Cl)=O.ClC=1C=CC=C2CCC(C12)N Chemical group ClC=1C=C2CCC(C2=C(C1)Cl)=O.ClC=1C=CC=C2CCC(C12)N DDLFFKOZDWUFOE-UHFFFAOYSA-N 0.000 description 1
• NMSANLQPPHRADX-ZDUSSCGKSA-N ClC=1C=C2CC[C@@H](C2=C(C=1)Cl)NC(=O)C=1C=NC=CC=1 Chemical compound ClC=1C=C2CC[C@@H](C2=C(C=1)Cl)NC(=O)C=1C=NC=CC=1 NMSANLQPPHRADX-ZDUSSCGKSA-N 0.000 description 1
• NMSANLQPPHRADX-CYBMUJFWSA-N ClC=1C=C2CC[C@H](C2=C(C=1)Cl)NC(=O)C=1C=NC=CC=1 Chemical compound ClC=1C=C2CC[C@H](C2=C(C=1)Cl)NC(=O)C=1C=NC=CC=1 NMSANLQPPHRADX-CYBMUJFWSA-N 0.000 description 1
• 208000015943 Coeliac disease Diseases 0.000 description 1
• 208000009248 Congenital Hip Dislocation Diseases 0.000 description 1
• 206010010741 Conjunctivitis Diseases 0.000 description 1
• 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
• 241000711573 Coronaviridae Species 0.000 description 1
• 108010091326 Cryoglobulins Proteins 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 206010011793 Cystitis haemorrhagic Diseases 0.000 description 1
• 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
• 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
• 206010051055 Deep vein thrombosis Diseases 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012434 Dermatitis allergic Diseases 0.000 description 1
• ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
• 238000007355 Double Michael addition reaction Methods 0.000 description 1
• 208000019872 Drug Eruptions Diseases 0.000 description 1
• 206010014950 Eosinophilia Diseases 0.000 description 1
• 206010065563 Eosinophilic bronchitis Diseases 0.000 description 1
• 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
• 208000010228 Erectile Dysfunction Diseases 0.000 description 1
• 206010015218 Erythema multiforme Diseases 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 208000001860 Eye Infections Diseases 0.000 description 1
• XGPBTQNJXPKDDI-UHFFFAOYSA-N FC(C1=CC=C(C=O)C=C1)(F)F.C1(CC1)C1=NC=C(C=N1)C(CN)N1CCOCC1 Chemical group FC(C1=CC=C(C=O)C=C1)(F)F.C1(CC1)C1=NC=C(C=N1)C(CN)N1CCOCC1 XGPBTQNJXPKDDI-UHFFFAOYSA-N 0.000 description 1
• DURITBMYBFMKJX-UHFFFAOYSA-N FC(C1=CC=C(C=O)C=C1)(F)F.COC1=CC=C(C=N1)C(CN)N1CCOCC1 Chemical group FC(C1=CC=C(C=O)C=C1)(F)F.COC1=CC=C(C=N1)C(CN)N1CCOCC1 DURITBMYBFMKJX-UHFFFAOYSA-N 0.000 description 1
• RYNLCCJTDCSPEB-UHFFFAOYSA-N FC(C1=CC=C(C=O)C=C1)(F)F.FC1(CCN(CC1)C(C#N)C1=CC=C(C=C1)C(F)(F)F)F Chemical compound FC(C1=CC=C(C=O)C=C1)(F)F.FC1(CCN(CC1)C(C#N)C1=CC=C(C=C1)C(F)(F)F)F RYNLCCJTDCSPEB-UHFFFAOYSA-N 0.000 description 1
• DITVNURISHKTBB-UHFFFAOYSA-N FC1(CCN(CC1)C(C#N)C1=CC=C(C=C1)C(F)(F)F)F.FC1(CCN(CC1)C(CN)C1=CC=C(C=C1)C(F)(F)F)F Chemical compound FC1(CCN(CC1)C(C#N)C1=CC=C(C=C1)C(F)(F)F)F.FC1(CCN(CC1)C(CN)C1=CC=C(C=C1)C(F)(F)F)F DITVNURISHKTBB-UHFFFAOYSA-N 0.000 description 1
• PJWBHAFYICCCPS-UHFFFAOYSA-N FC1(CCNCC1)F.CC1=CC=C(C=N1)C=O Chemical group FC1(CCNCC1)F.CC1=CC=C(C=N1)C=O PJWBHAFYICCCPS-UHFFFAOYSA-N 0.000 description 1
• GFZJTRCZAXVKEJ-UHFFFAOYSA-N FC1(CCOC2=NC=CC=C21)C#N.FC2(CCOC1=NC=CC=C12)C(=O)O Chemical compound FC1(CCOC2=NC=CC=C21)C#N.FC2(CCOC1=NC=CC=C12)C(=O)O GFZJTRCZAXVKEJ-UHFFFAOYSA-N 0.000 description 1
• QWNNDYVMPRMVNH-UHFFFAOYSA-N FC1(COC2=NC=CC=C21)C(=O)O.FC2(COC1=NC=CC=C12)C(=O)O Chemical compound FC1(COC2=NC=CC=C21)C(=O)O.FC2(COC1=NC=CC=C12)C(=O)O QWNNDYVMPRMVNH-UHFFFAOYSA-N 0.000 description 1
• 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
• 208000032678 Fixed drug eruption Diseases 0.000 description 1
• 208000005232 Glossitis Diseases 0.000 description 1
• 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 208000003695 Histiocytic Necrotizing Lymphadenitis Diseases 0.000 description 1
• 206010069070 Histiocytic necrotising lymphadenitis Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 description 1
• 208000004575 Infectious Arthritis Diseases 0.000 description 1
• 102000003810 Interleukin-18 Human genes 0.000 description 1
• 108090000171 Interleukin-18 Proteins 0.000 description 1
• 206010022941 Iridocyclitis Diseases 0.000 description 1
• 208000015282 Kikuchi-Fujimoto disease Diseases 0.000 description 1
• 108010092694 L-Selectin Proteins 0.000 description 1
• 102000016551 L-selectin Human genes 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 239000012097 Lipofectamine 2000 Substances 0.000 description 1
• 208000008930 Low Back Pain Diseases 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• 238000006458 Meerwein arylation reaction Methods 0.000 description 1
• 206010027476 Metastases Diseases 0.000 description 1
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
• 208000019022 Mood disease Diseases 0.000 description 1
• 241000699670 Mus sp. Species 0.000 description 1
• 206010070757 Muscle contusion Diseases 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• FCYTXHWIYXTRHV-UHFFFAOYSA-N N-[(2,4-dichloro-6-methylphenyl)methyl]pyridine-3-carboxamide Chemical compound ClC1=C(CNC(=O)C=2C=NC=CC=2)C(=CC(=C1)Cl)C FCYTXHWIYXTRHV-UHFFFAOYSA-N 0.000 description 1
• 150000001204 N-oxides Chemical class 0.000 description 1
• 208000000592 Nasal Polyps Diseases 0.000 description 1
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
• POLGGKHDYYJREV-UHFFFAOYSA-N O1C=C(C=2C1=NC=CC2)C=O.O2C=C(C=1C2=NC=CC1)C(=O)O Chemical compound O1C=C(C=2C1=NC=CC2)C=O.O2C=C(C=1C2=NC=CC1)C(=O)O POLGGKHDYYJREV-UHFFFAOYSA-N 0.000 description 1
• AFWPIKUFZMVMAH-UHFFFAOYSA-N O1CCC(C=2C1=NC=CC2)O.ClC2CCOC1=NC=CC=C12 Chemical compound O1CCC(C=2C1=NC=CC2)O.ClC2CCOC1=NC=CC=C12 AFWPIKUFZMVMAH-UHFFFAOYSA-N 0.000 description 1
• GLOYDOFULVDBIZ-UHFFFAOYSA-N O1CCCC=2C1=NC=CC2.FC2(CCOC1=NC=CC=C12)C#N Chemical compound O1CCCC=2C1=NC=CC2.FC2(CCOC1=NC=CC=C12)C#N GLOYDOFULVDBIZ-UHFFFAOYSA-N 0.000 description 1
• XNFHBTPNTKEZRY-UHFFFAOYSA-N OC(=O)C1(F)CCOc2ncccc12 Chemical compound OC(=O)C1(F)CCOc2ncccc12 XNFHBTPNTKEZRY-UHFFFAOYSA-N 0.000 description 1
• KVPWQRLRXSPPDU-UHFFFAOYSA-N OC(=O)C1(F)COc2ncccc12 Chemical compound OC(=O)C1(F)COc2ncccc12 KVPWQRLRXSPPDU-UHFFFAOYSA-N 0.000 description 1
• 208000027771 Obstructive airways disease Diseases 0.000 description 1
• 206010030216 Oesophagitis Diseases 0.000 description 1
• 206010031252 Osteomyelitis Diseases 0.000 description 1
• 206010034277 Pemphigoid Diseases 0.000 description 1
• 241000721454 Pemphigus Species 0.000 description 1
• 208000004362 Penile Induration Diseases 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 208000020758 Peyronie disease Diseases 0.000 description 1
• 208000004983 Phantom Limb Diseases 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 206010036774 Proctitis Diseases 0.000 description 1
• 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
• 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
• 208000006311 Pyoderma Diseases 0.000 description 1
• 206010063837 Reperfusion injury Diseases 0.000 description 1
• 208000025747 Rheumatic disease Diseases 0.000 description 1
• 206010039094 Rhinitis perennial Diseases 0.000 description 1
• 208000036284 Rhinitis seasonal Diseases 0.000 description 1
• 206010039710 Scleroderma Diseases 0.000 description 1
• 208000034189 Sclerosis Diseases 0.000 description 1
• 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 208000009359 Sezary Syndrome Diseases 0.000 description 1
• 208000021388 Sezary disease Diseases 0.000 description 1
• 229910020175 SiOH Inorganic materials 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 208000010265 Sweet syndrome Diseases 0.000 description 1
• 239000012317 TBTU Substances 0.000 description 1
• 206010057970 Toxic skin eruption Diseases 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
• 208000025851 Undifferentiated connective tissue disease Diseases 0.000 description 1
• 208000017379 Undifferentiated connective tissue syndrome Diseases 0.000 description 1
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
• 208000024780 Urticaria Diseases 0.000 description 1
• 206010047249 Venous thrombosis Diseases 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• 208000027418 Wounds and injury Diseases 0.000 description 1
• 208000035222 X-linked skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
• NQZLAWXEGDYJPY-UHFFFAOYSA-N [1-(6-chloropyridin-3-yl)-4,4-difluorocyclohexyl]methanamine Chemical compound C=1C=C(Cl)N=CC=1C1(CN)CCC(F)(F)CC1 NQZLAWXEGDYJPY-UHFFFAOYSA-N 0.000 description 1
• WGKLOQLMHWEISI-UHFFFAOYSA-N [2,4-dichloro-6-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=C(Cl)C=C(Cl)C=C1C(F)(F)F WGKLOQLMHWEISI-UHFFFAOYSA-N 0.000 description 1
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
• 210000000683 abdominal cavity Anatomy 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 206010000496 acne Diseases 0.000 description 1
• 238000004115 adherent culture Methods 0.000 description 1
• 230000001464 adherent effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 208000002353 alcoholic hepatitis Diseases 0.000 description 1
• 125000006231 alkoxy propyl group Chemical group 0.000 description 1
• 125000005083 alkoxyalkoxy group Chemical group 0.000 description 1
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
• 125000004848 alkoxyethyl group Chemical group 0.000 description 1
• 201000009961 allergic asthma Diseases 0.000 description 1
• 208000002205 allergic conjunctivitis Diseases 0.000 description 1
• 201000010105 allergic rhinitis Diseases 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 208000004631 alopecia areata Diseases 0.000 description 1
• 150000003862 amino acid derivatives Chemical class 0.000 description 1
• 150000001414 amino alcohols Chemical class 0.000 description 1
• 125000005219 aminonitrile group Chemical group 0.000 description 1
• 150000001448 anilines Chemical class 0.000 description 1
• 230000000954 anitussive effect Effects 0.000 description 1
• 201000004612 anterior uveitis Diseases 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 229940124584 antitussives Drugs 0.000 description 1
• 229910052586 apatite Inorganic materials 0.000 description 1
• 230000006907 apoptotic process Effects 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 208000024998 atopic conjunctivitis Diseases 0.000 description 1
• 150000001540 azides Chemical class 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000005605 benzo group Chemical group 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• XGIUDIMNNMKGDE-UHFFFAOYSA-N bis(trimethylsilyl)azanide Chemical compound C[Si](C)(C)[N-][Si](C)(C)C XGIUDIMNNMKGDE-UHFFFAOYSA-N 0.000 description 1
• 208000010217 blepharitis Diseases 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• 238000005893 bromination reaction Methods 0.000 description 1
• 150000001649 bromium compounds Chemical group 0.000 description 1
• LOXORFRCPXUORP-UHFFFAOYSA-N bromo-Cycloheptane Chemical compound BrC1CCCCCC1 LOXORFRCPXUORP-UHFFFAOYSA-N 0.000 description 1
• 201000009267 bronchiectasis Diseases 0.000 description 1
• 239000000872 buffer Substances 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 206010007604 cardiac sarcoidosis Diseases 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 208000010353 central nervous system vasculitis Diseases 0.000 description 1
• 208000036319 cervical spondylosis Diseases 0.000 description 1
• 208000002849 chondrocalcinosis Diseases 0.000 description 1
• 208000013116 chronic cough Diseases 0.000 description 1
• 208000017760 chronic graft versus host disease Diseases 0.000 description 1
• 201000009151 chronic rhinitis Diseases 0.000 description 1
• GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
• 238000010367 cloning Methods 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 229940125782 compound 2 Drugs 0.000 description 1
• 238000009833 condensation Methods 0.000 description 1
• 230000005494 condensation Effects 0.000 description 1
• 238000006482 condensation reaction Methods 0.000 description 1
• 208000018631 connective tissue disease Diseases 0.000 description 1
• DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
• 239000012043 crude product Substances 0.000 description 1
• 239000013078 crystal Substances 0.000 description 1
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
• 125000004981 cycloalkylmethyl group Chemical group 0.000 description 1
• 230000006378 damage Effects 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 238000006114 decarboxylation reaction Methods 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 208000018180 degenerative disc disease Diseases 0.000 description 1
• 230000003412 degenerative effect Effects 0.000 description 1
• 239000012024 dehydrating agents‎ Substances 0.000 description 1
• 230000018044 dehydration Effects 0.000 description 1
• 238000006297 dehydration reaction Methods 0.000 description 1
• 230000003210 demyelinating effect Effects 0.000 description 1
• 125000004431 deuterium atom Chemical group 0.000 description 1
• 208000014906 developmental dysplasia of the hip Diseases 0.000 description 1
• WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 208000010643 digestive system disease Diseases 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
• MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 239000000428 dust Substances 0.000 description 1
• 206010014665 endocarditis Diseases 0.000 description 1
• 210000002889 endothelial cell Anatomy 0.000 description 1
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
• 206010015037 epilepsy Diseases 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 208000006881 esophagitis Diseases 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
• FZSMFBPOVGYFEA-UHFFFAOYSA-N ethyl 2-tributylstannylacetate Chemical compound CCCC[Sn](CCCC)(CCCC)CC(=O)OCC FZSMFBPOVGYFEA-UHFFFAOYSA-N 0.000 description 1
• FPROWCZUJRYEQI-UHFFFAOYSA-N ethyl 3-(2-chloropyridin-3-yl)-3-hydroxypropanoate Chemical compound CCOC(=O)CC(O)C1=CC=CN=C1Cl FPROWCZUJRYEQI-UHFFFAOYSA-N 0.000 description 1
• PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 208000024711 extrinsic asthma Diseases 0.000 description 1
• 239000012091 fetal bovine serum Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 208000012587 fixed pigmented erythema Diseases 0.000 description 1
• 238000000799 fluorescence microscopy Methods 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 230000006870 function Effects 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• VZDJNNDWQDPDIH-UHFFFAOYSA-N furo[2,3-b]pyridine-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=COC2=N1 VZDJNNDWQDPDIH-UHFFFAOYSA-N 0.000 description 1
• 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
• 208000018685 gastrointestinal system disease Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 230000003676 hair loss Effects 0.000 description 1
• 210000002216 heart Anatomy 0.000 description 1
• 201000002802 hemorrhagic cystitis Diseases 0.000 description 1
• 208000006454 hepatitis Diseases 0.000 description 1
• 231100000283 hepatitis Toxicity 0.000 description 1
• 210000001320 hippocampus Anatomy 0.000 description 1
• 210000003630 histaminocyte Anatomy 0.000 description 1
• 150000002431 hydrogen Chemical class 0.000 description 1
• 230000000642 iatrogenic effect Effects 0.000 description 1
• 229940088592 immunologic factor Drugs 0.000 description 1
• 239000000367 immunologic factor Substances 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 238000007901 in situ hybridization Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000004129 indan-1-yl group Chemical group [H]C1=C([H])C([H])=C2C(=C1[H])C([H])([H])C([H])([H])C2([H])* 0.000 description 1
• 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• SNWQUNCRDLUDEX-UHFFFAOYSA-N inden-1-one Chemical compound C1=CC=C2C(=O)C=CC2=C1 SNWQUNCRDLUDEX-UHFFFAOYSA-N 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 201000009863 inflammatory diarrhea Diseases 0.000 description 1
• 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 208000021600 intervertebral disc degenerative disease Diseases 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
• 201000010659 intrinsic asthma Diseases 0.000 description 1
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 230000000155 isotopic effect Effects 0.000 description 1
• 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 230000001589 lymphoproliferative effect Effects 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910001641 magnesium iodide Inorganic materials 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 208000008585 mastocytosis Diseases 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
• DBKFYOHGPURQCZ-UHFFFAOYSA-N methyl 2-bromo-3-chlorobenzoate Chemical compound COC(=O)C1=CC=CC(Cl)=C1Br DBKFYOHGPURQCZ-UHFFFAOYSA-N 0.000 description 1
• LAEKWGYLESVYHG-UHFFFAOYSA-N methyl 3-chloro-2-cyanobenzoate Chemical compound COC(=O)C1=CC=CC(Cl)=C1C#N LAEKWGYLESVYHG-UHFFFAOYSA-N 0.000 description 1
• 150000004702 methyl esters Chemical class 0.000 description 1
• YMNBJUCMFGAAJQ-UHFFFAOYSA-N methyl furo[2,3-b]pyridine-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=COC2=N1 YMNBJUCMFGAAJQ-UHFFFAOYSA-N 0.000 description 1
• 210000000274 microglia Anatomy 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 238000010369 molecular cloning Methods 0.000 description 1
• 239000002808 molecular sieve Substances 0.000 description 1
• 201000006938 muscular dystrophy Diseases 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• LLYKPZOWCPVRPD-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine;n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=CC=N1 LLYKPZOWCPVRPD-UHFFFAOYSA-N 0.000 description 1
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
• WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 210000004498 neuroglial cell Anatomy 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 230000001473 noxious effect Effects 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 230000011164 ossification Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• OTYPIDNRISCWQY-UHFFFAOYSA-L palladium(2+);tris(2-methylphenyl)phosphane;dichloride Chemical compound Cl[Pd]Cl.CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C.CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C OTYPIDNRISCWQY-UHFFFAOYSA-L 0.000 description 1
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 206010033675 panniculitis Diseases 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 208000035824 paresthesia Diseases 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
• 208000000689 peptic esophagitis Diseases 0.000 description 1
• 208000022719 perennial allergic rhinitis Diseases 0.000 description 1
• 208000008494 pericarditis Diseases 0.000 description 1
• 230000003836 peripheral circulation Effects 0.000 description 1
• 210000002856 peripheral neuron Anatomy 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 125000005359 phenoxyalkyl group Chemical group 0.000 description 1
• 208000001297 phlebitis Diseases 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 208000017983 photosensitivity disease Diseases 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
• 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
• 239000011148 porous material Substances 0.000 description 1
• 230000001242 postsynaptic effect Effects 0.000 description 1
• LBKJNHPKYFYCLL-UHFFFAOYSA-N potassium;trimethyl(oxido)silane Chemical compound [K+].C[Si](C)(C)[O-] LBKJNHPKYFYCLL-UHFFFAOYSA-N 0.000 description 1
• 239000002243 precursor Substances 0.000 description 1
• 230000003518 presynaptic effect Effects 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 230000037452 priming Effects 0.000 description 1
• 238000012545 processing Methods 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 201000007094 prostatitis Diseases 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 208000002815 pulmonary hypertension Diseases 0.000 description 1
• 238000004451 qualitative analysis Methods 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 239000000376 reactant Substances 0.000 description 1
• 238000006268 reductive amination reaction Methods 0.000 description 1
• 230000002829 reductive effect Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 230000000552 rheumatic effect Effects 0.000 description 1
• 229920002477 rna polymer Polymers 0.000 description 1
• 208000017022 seasonal allergic rhinitis Diseases 0.000 description 1
• 208000008742 seborrheic dermatitis Diseases 0.000 description 1
• 201000001223 septic arthritis Diseases 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 208000025869 skeletal dysplasia-intellectual disability syndrome Diseases 0.000 description 1
• 201000000849 skin cancer Diseases 0.000 description 1
• 230000037380 skin damage Effects 0.000 description 1
• 201000003646 skin sarcoidosis Diseases 0.000 description 1
• URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
• SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 208000003001 spinal tuberculosis Diseases 0.000 description 1
• 208000005801 spondylosis Diseases 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
• 150000003462 sulfoxides Chemical class 0.000 description 1
• 230000005062 synaptic transmission Effects 0.000 description 1
• 230000008409 synovial inflammation Effects 0.000 description 1
• 201000004595 synovitis Diseases 0.000 description 1
• 210000002435 tendon Anatomy 0.000 description 1
• WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
• 229930192474 thiophene Natural products 0.000 description 1
• 125000003944 tolyl group Chemical group 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 1
• AAPLIUHOKVUFCC-UHFFFAOYSA-N trimethylsilanol Chemical compound C[Si](C)(C)O AAPLIUHOKVUFCC-UHFFFAOYSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• 230000005951 type IV hypersensitivity Effects 0.000 description 1
• 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 208000000143 urethritis Diseases 0.000 description 1
• 229940116269 uric acid Drugs 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 210000005166 vasculature Anatomy 0.000 description 1
• 230000003156 vasculitic effect Effects 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 208000009935 visceral pain Diseases 0.000 description 1
• 208000010484 vulvovaginitis Diseases 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229940102001 zinc bromide Drugs 0.000 description 1